

Supporting Information

Enantioselective Construction of Spiro-Tetrahydroquinoline

Scaffolds through Asymmetric Catalytic Cascade Reactions.

Jia-Lu Zhang¹, Rui Ma¹, Huan-Huan Zhao¹, and Peng-Fei Xu^{1,2*}

¹State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, P. R. China.

²State Key Laboratory of Veterinary Etiological Biology, College of Veterinary Medicine, Lanzhou University, 730000, P. R. China

CONTENTS

Supporting Information.....	1
1. General Information.....	2
2. General Procedure and Spectral Data of Products	2
2.1 Preparation of Substrate 2.	2
2.2 Optimization of <i>aza</i> -Michael addition reaction of 1a and 2a.	3
2.3 Spectral Data of Substrates.	4
2.4 Analytical data of compounds of 3.....	8
2.5 Analytical data of compounds of 4.....	21
3. General Procedure to Synthesize the Spiro-Tetrahydroquinoline Derivatives 3.....	21
3.1. General procedure to construct spiro-tetrahydroquinoline derivatives.	21
3.2. A gram-scale synthesis of 3la.	22
3.3. General procedure to synthesis 4la.....	22
4. Copy of NMR Spectrogram.	22
4.1 Copy of NMR Spectrogram of 2.	22
4.2 Copy of NMR Spectrogram of 3	39
4.3 Copy of NMR Spectrogram of 4.....	79
5. HPLC spectrogram.....	81
5.1. HPLC spectrogram of compound 3.....	81
5.2. HPLC spectrogram of compound 4.....	121
6. X-ray crystallographic data	122
7. References.....	124


1. General Information

Chemicals and solvents were either purchased from commercial suppliers or purified by standard techniques. tetrahydrofuran (THF), dichloromethane (DCM), 1,2-dichloroethane (DCE), toluene, acetonitrile (MeCN) were dried by passage through alumina using a Pure-Solv PS-MD-5 Solvent Purification System (Innovative Technology). Analytical thin-layer chromatography (TLC) was performed on silicycle silica gel plates with F-254 indicator and compounds were visualized by irradiation with UV light. Flash chromatography was carried out utilizing silica gel 200-300 mesh. ^1H NMR, ^{13}C NMR spectra were recorded on a Bruker AM-400 spectrometer (400 MHz ^1H , 100 MHz ^{13}C). The spectra were recorded in CDCl_3 and DMSO as the solvent at room temperature, ^1H and ^{13}C NMR chemical shifts are reported in ppm relative to either the residual solvent peak (^{13}C) ($\delta = 77.00$ ppm, $\delta = 39.51$ ppm) or TMS (^1H) ($\delta = 0$ ppm, $\delta = 2.50$ ppm) as an internal standard. Data for ^1H NMR are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = double, t = triplet, m = multiplet, dd = double doublet), integration, coupling constant (Hz) and assignment. Data for ^{13}C NMR are reported as chemical shift. HRMS were performed on Bruker Apex II mass instrument (ESI). Enantiomeric excess values were determined by HPLC with Daicel Chirapak IA column on Agilent 1260 series with *i*-PrOH and *n*-hexane. Optical rotation was measured on the Perkin Elmer 341 polarimeter with $[\alpha]_{\text{D}}$ values reported in degrees. Concentration (c) is in g/100 mL. The irradiation vessels were purchased from <http://www.xinweier.com/>.

2. General Procedure and Spectral Data of Products


2.1 Preparation of Substrate 2.

The generation of synthesis compounds 2.




A solution of 2-coumaranone (S_1 , 20 mmol), substituted benzaldehydes (S_2 , 20 mmol) and P-toluenesulfonic acid (20 mol%) were added to 40 mL toluene in a 100 mL flame-dried round bottom, which was refluxed overnight. After cooling to room temperature, the solvent was evaporated under reduced vacuum, and the residues were purified by flash silica gel chromatograph to obtain the crude products, which were recrystallized from PE and EA to afford the pure compounds.


The precursors of **2q**, **2r** were synthesized after the minor modification of the reported literatures², which are shown as follows:



To a 100 mL round-bottom flask, 2-benzofuranone (2-coumaranone, 1.92 g, 14.3 mmol), N-chlorosuccinimide (5.72 g, 42.6 mmol) and anhydrous CH₃CN (50 mL) were added and the solution was vigorously stirred for 3 days. CH₃CN was then evaporated and the residue was diluted with toluene. The organic solution was washed with one portion of Na₂S₂O₃ (aq) and two portions of H₂O, then dried over Na₂SO₄. After removal of the Na₂SO₄, the solvent was evaporated and the residue was purified by silica gel column chromatography (PE/EA/DCM = 10/1/2) to afford the desired product as a yellow solid.




To a 100 mL round flask was added 1-(2-hydroxy-5-methylphenyl)ethanone (15 g, 100 mmol), sulfur (6.4 g, 200 mmol), morpholine (20 mL) and p-toluene sulphonic acid (0.665 g, 3.5 mmol). Then the solution was heated under constant stirring in an oil bath at 130 °C for 8 h. After completion of the reaction as monitored by TLC, the reaction mixture was allowed to cool and 20% NaOH and triethyl benzyl ammonium chloride S₃ (TEBA) (570 mg, 0.25 mmol) were added. The reaction mixture continued hydrolysis at 100 °C for additional 8 h. After cooling to the room temperature, 50 mL of DCM was added to the system and the residue was stirred at rt. for 0.5 h, then the system was acidified with HCl (0.3 M) to pH 6, extracted with DCM (3x50 mL), H₂O, brine, dried over anhydrous Na₂SO₄, evaporated under reduced pressure and the residue was purified by silica gel column chromatography (PE/EA/DCM = 5/1/2) to afford the desired product as a yellow solid.



A solution of 2-(2-hydroxy-5-methylphenyl)acetic acid (20 mmol), P-toluenesulfonic acid (20 mol%) were added to 40 mL toluene in a 100 mL flame-dried round bottom, which was refluxed overnight. After cooling to room temperature, the solvent was evaporated under reduced vacuum, and the residues were purified by flash silica gel chromatography to obtain the crude products, which were recrystallized from PE and EA to afford the pure compounds.

Compound **1** can be synthesized by the reported literature¹.


2.2 Optimization of *aza*-Michael addition reaction of **1a** and **2a**.



entry	cat.	solvent	T (h)	yield (%) ^c	dr ^d	ee (%) ^e
-------	------	---------	-------	------------------------	-----------------	---------------------


1	I	DCE	50	25	>20:1	97
2	II	DCE	50	23	>20:1	99
3	III	DCE	50	85	>20:1	-97
4	IV	DCE	50	n.r.	--	--
5	V	DCE	50	50	>20:1	94
6	VI	DCE	50	65	>20:1	97
7	VII	DCE	50	91	>20:1	96
8	VIII	DCE	50	99	>20:1	97
9	VIII	Toluene	52	88	>20:1	97
10	VIII	DCM	50	99	>20:1	96
11	VIII	CH ₃ Cl	50	86	>20:1	96
12	VIII	EA	60	86	>20:1	97
13	VIII	THF	60	40	>20:1	96
14	VIII	MeCN	60	61	>20:1	96
15 ^a	VIII	DCE	46	99	>20:1	97
16 ^b	VIII	DCE	44	99	>20:1	97

Unless otherwise noted, the reactions were conducted with **1a** (0.11 mmol), **2a** (0.1 mmol), and 20 mol % of the catalyst, in solvent (1.0 mL) at rt. for 44 h. ^a0.15 mmol of **1a** was added, ^b0.2 mmol of **2a** was added. ^cIsolated yield. ^dDetermined by ¹H NMR. ^eDetermined by chiral-phase HPLC analysis.




2.3 Spectral Data of Substrates.

(E)-3-benzylidenebenzofuran-2(3H)-one (**2a**)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.11g, 45% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.86 (d, *J* = 3.16 Hz, 1H), 7.73 (d, *J* = 7.80 Hz, 1H), 7.69-7.66 (m, 2H), 7.52-7.45 (m, 3H), 7.36-7.31 (m, 1H), 7.12 (dd, *J* = 2.52 Hz, *J* = 8.02 Hz, 1H), 7.03 (td, *J* = 7.70 Hz, *J* = 1.00 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.8, 154.3, 140.9, 133.9, 130.8, 130.4, 129.3, 128.7, 123.6, 122.7, 122.1, 121.7, 111.1.


(Z)-3-(2-methoxybenzylidene)benzofuran-2(3H)-one (**2b**)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.35g, 48% yield). ¹H


NMR (400 MHz, CDCl₃) δ = 8.03 (s, 1H), 7.72 (d, J = 7.24 Hz, 1H), 7.63 (d, J = 7.60 Hz, 1H), 7.45 (t, J = 7.88 Hz, 1H), 7.31-7.25 (m, 1H), 7.09 (d, J = 8.14 Hz, 1H), 7.05-6.97 (m, 3H), 3.87 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.8, 158.0, 154.0, 137.2, 132.4, 130.3, 129.3, 123.3, 122.7, 122.5, 122.0, 121.4, 120.0, 110.9, 110.8, 55.4.

(Z)-3-(3-methoxybenzylidene)benzofuran-2(3H)-one (2c)




Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.35g, 48% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.81 (s, 1H), 7.75 (d, J = 7.72 Hz, 1H), 7.40 (d, J = 7.92 Hz, 1H), 7.35-7.31 (m, 1H), 7.25 (d, J = 7.56 Hz, 1H), 7.16 (s, 1H), 7.12 (d, J = 7.96 Hz, 1H), 7.05-6.99 (m, 2H), 3.84 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.8, 159.6, 154.4, 140.7, 135.1, 130.8, 129.8, 123.5, 122.9, 122.2, 121.6, 121.6, 116.2, 114.2, 111.1, 55.3.

(Z)-3-(4-methoxybenzylidene)benzofuran-2(3H)-one (2d)




Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.35g, 48% yield). ¹H NMR (400 MHz, CDCl₃) δ = 8.22 (d, J = 8.18 Hz, 2H), 7.46-7.43 (m, 2H), 7.24 (t, J = 7.46 Hz, 1H), 7.11 (d, J = 7.30 Hz, 1H), 7.03 (d, J = 7.82 Hz, 1H), 6.92 (d, J = 8.14 Hz, 2H), 3.82 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 166.2, 162.1, 152.3, 140.1, 134.5, 128.8, 126.2, 125.8, 123.4, 118.7, 117.5, 113.9, 110.4, 55.3.

(Z)-3-(2-fluorobenzylidene)benzofuran-2(3H)-one (2e)




Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 46% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.83 (s, 1H), 7.72 (t, J = 7.30 Hz, 1H), 7.53 (d, J = 8.02 Hz, 1H), 7.48 (m, 1H), 7.34 (t, J = 7.64 Hz, 1H), 7.27 (t, J = 7.36 Hz, 1H), 7.19 (t, J = 8.08 Hz, 1H), 7.10 (d, J = 7.94 Hz, 1H), 7.03 (t, J = 7.66 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.2, 160.4 (J = 253.8 Hz), 154.5, 132.9 (J = 3.4 Hz), 132.4 (J = 8.4 Hz), 131.2, 129.8 (J = 2.2 Hz), 124.1 (J = 3.6 Hz), 123.9, 123.7, 122.9 (J = 1.4 Hz), 122.1 (J = 14.6 Hz), 121.5, 116.2 (J = 21.4), 111.1.

(Z)-3-(3-fluorobenzylidene)benzofuran-2(3H)-one (2f)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 41% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.75 (s, 1H), 7.66 (d, J = 7.74 Hz, 1H), 7.53-7.40 (m, 2H), 7.36-7.32 (m, 2H), 7.19-7.10 (m, 2H), 7.04 (td, J = 7.72 Hz, J = 0.90 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.4, 162.6 (J = 248.1 Hz), 154.5, 138.7 (J = 2.2 Hz), 135.9 (J = 7.9 Hz), 131.3, 130.4 (J = 8.5 Hz), 124.9 (J = 2.9 Hz), 123.7, 123.2, 122.8, 121.2, 119.5, 117.2 (J = 21.2), 115.7 (J = 22.2 Hz), 111.2.


(Z)-3-(4-fluorobenzylidene)benzofuran-2(3H)-one (2g)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 50% yield). ¹H

NMR (400 MHz, CDCl₃) δ = 7.76 (s, 1H), 7.66 (d, J = 7.74 Hz, 1H), 7.50-7.42 (m, 2H), 7.34 (t, J = 7.86 Hz, 2H), 7.18-7.14 (m, 1H), 7.11 (d, J = 8.22 Hz, 1H), 7.04 (t, J = 7.70 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.3, 162.6 (J = 248.0 Hz), 154.5, 138.7 (J = 2.3 Hz), 135.9 (J = 7.9 Hz), 131.3, 130.4 (J = 8.2 Hz), 124.9 (J = 2.9 Hz), 123.7, 123.2, 122.8, 122.2, 121.5, 117.2 (J = 21.1), 115.7 (J = 20.1 Hz), 111.2.


(Z)-3-(2-chlorobenzylidene)benzofuran-2(3H)-one (2h)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 46% yield).¹H

NMR (400 MHz, CDCl₃) δ = 7.91 (s, 1H), 7.74 (dd, J = 1.64 Hz, J = 7.42 Hz, 1H), 7.51 (d, J = 1.28 Hz, J = 7.98 Hz, 1H), 7.45-7.38 (m, 3H), 7.36-7.32 (m, 1H), 7.11 (d, J = 8.02 Hz, 1H), 7.00 (td, J = 0.70 Hz, J = 7.64 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.1, 154.4, 136.9, 134.4, 132.4, 131.4, 131.2, 130.1, 129.6, 126.6, 123.7, 123.6, 122.8, 121.2, 111.1.


(Z)-3-(2-chlorobenzylidene)benzofuran-2(3H)-one (2i)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 46% yield).¹H

NMR (400 MHz, CDCl₃) δ = 7.75 (s, 1H), 7.64 (d, J = 8.00 Hz, 2H), 7.54 (d, J = 3.88 Hz, 1H), 7.44 (d, J = 4.50 Hz, 1H), 7.36 (t, J = 7.72 Hz, 1H), 7.14 (d, J = 8.12 Hz, 1H), 7.06 (t, J = 7.64 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.4, 154.5, 138.6, 135.6, 134.8, 131.3, 130.2, 130.1, 128.9, 127.2, 123.8, 123.3, 122.7, 121.3, 111.3.

(Z)-3-(4-chlorobenzylidene)benzofuran-2(3H)-one (2j)




Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 46% yield).¹H

NMR (400 MHz, CDCl₃) δ = 7.76 (s, 1H), 7.67-7.60 (m, 3H), 7.45 (d, J = 5.58 Hz, 2H), 7.34 (s, 1H), 7.13-7.04 (m, 2H). ¹³C NMR (100 MHz, CDCl₃)

δ = 168.5, 154.4, 139.0, 136.3, 132.2, 131.1, 130.5, 129.0, 123.6, 122.5, 121.3, 111.2.

(Z)-3-(2-bromobenzylidene)benzofuran-2(3H)-one (2k)




Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 46% yield).¹H

NMR (400 MHz, CDCl₃) δ = 7.86 (s, 1H), 7.72 (t, J = 6.44 Hz, 2H), 7.45-7.39 (m, 2H), 7.34 (t, J = 7.88 Hz, 2H), 7.12 (d, J = 8.00 Hz, 1H), 6.99 (t, J = 7.66

Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.1, 154.4, 139.0, 134.3, 133.3, 131.5, 131.2, 129.7, 127.3, 124.3, 123.6, 123.5, 122.8, 121.3, 111.2.


(Z)-3-(3-bromobenzylidene)benzofuran-2(3H)-one (2l)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 46% yield).¹H

NMR (400 MHz, CDCl₃) δ = 7.78 (s, 1H), 7.74 (s, 1H), 7.63 (d, J = 7.82 Hz, 1H), 7.58 (d, J = 7.86 Hz, 1H), 7.39-7.34 (m, 2H), 7.13 (d, J = 8.12 Hz, 1H), 7.05 (t, J = 7.72 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.3, 154.5, 138.5, 135.8, 133.1, 131.7, 131.3, 130.3, 127.6, 123.7, 123.3, 122.8, 122.6, 121.2, 111.2.

(Z)-3-(4-bromobenzylidene)benzofuran-2(3H)-one (2m)




Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.2g, 45% yield). ¹H

NMR (400 MHz, CDCl₃) δ = 7.75 (s, 1H), 7.68-7.62 (m, 3H), 7.54 (d, J = 8.16 Hz, 2H), 7.36 (t, J = 7.66 Hz, 1H), 7.14 (d, J = 8.34 Hz, 1H), 7.05 (t, J =

7.52 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.5, 154.4, 139.8, 132.7, 132.0, 131.2, 130.7, 124.7, 123.7, 122.6, 122.6, 121.4, 111.3.

(Z)-3-(2,3-dichlorobenzylidene)benzofuran-2(3H)-one (2n)




Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.35g, 49% yield). ¹H

NMR (400 MHz, CDCl₃) δ = 7.86 (s, 1H), 7.64 (d, J = 7.98 Hz, 1H), 7.61-7.58 (m, 1H), 7.38-7.32 (m, 3H), 7.13 (d, J = 7.92 Hz, 1H), 7.00 (d, J = 7.68 Hz, 1H).

¹³C NMR (100 MHz, DMSO) δ = 167.8, 154.6, 136.1, 134.6, 134.1, 132.6, 131.8, 131.6, 127.7, 127.3, 124.4, 123.7, 122.9, 121.0, 111.3.


(Z)-3-(2,5-dichlorobenzylidene)benzofuran-2(3H)-one (2o)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.35g, 48% yield). ¹H

NMR (400 MHz, CDCl₃) δ = 7.81 (s, 1H), 7.71 (d, J = 2.16 Hz, 1H), 7.46 (d, J = 8.60 Hz, 1H), 7.40-7.38 (m, 3H), 7.15 (d, J = 8.06 Hz, 1H), 7.05 (t, J = 7.66 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 167.7, 154.8, 135.0, 134.0, 132.7, 131.8, 131.3, 131.1, 129.3, 124.8, 123.9, 122.8, 121.0, 111.4.


(Z)-3-(3,4-dichlorobenzylidene)benzofuran-2(3H)-one (2p)



Yellow solid (petroleum ether/EtOAc/CH₂Cl₂ = 7/1/2, 1.35g, 48% yield). ¹H

NMR (400 MHz, CDCl₃) δ = 7.74 (d, J = 4.56 Hz, 1H), 7.69 (s, 1H), 7.61 (d, J = 7.70 Hz, 1H), 7.57 (d, J = 8.28 Hz, 1H), 7.50 (dd, J = 1.60 Hz, J = 8.30 Hz, 1H), 7.39-7.35 (m, 1H), 7.14 (d, J = 8.08 Hz, 1H), 7.07 (t, J = 7.72 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.1, 154.7, 137.2, 134.4, 133.8, 133.2, 131.6, 130.9, 130.7, 128.2, 123.8, 123.7, 122.7, 121.1, 111.4.

(Z)-3-benzylidene-5-chlorobenzofuran-2(3H)-one (2q)




Orange yellow solid (petroleum ether/EtOAc = 15/1, 1.28g, 50% yield). ¹H

NMR (400 MHz, CDCl₃) δ = 7.74 (s, 1H), 7.64-7.61 (m, 2H), 7.53 (d, J = 3.76 Hz, 1H), 7.44 (d, J = 4.57 Hz, 2H), 7.35 (t, J = 7.88 Hz, 1H), 7.13 (d, J = 8.04 Hz, 1H), 7.05 (d, J = 7.62 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 168.3, 154.5, 138.6, 135.6, 134.7, 131.3, 130.2, 130.1, 128.8, 127.1, 123.7, 123.3,

122.7, 121.2, 111.2.


2.4 Analytical data of compounds of 3.

(2'R,3R,4'R)-4'-(2-oxo-2-phenylethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3aa).




White solid (119 mg, 99 %). PE/EA/DCM = 10/1/2, 164-166 °C. $[\alpha]_D^{24.7} = -26$ (c 1.0, CH₂Cl₂, 97 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.86 Hz, H), 7.72 (d, *J* = 7.56 Hz, 2H), 7.60 (t, *J* = 8.00 Hz, 2H), 7.52 (t, *J* = 6.25 Hz, 2H), 7.39 (t, *J* = 7.56 Hz, 2H), 7.31 (d, *J* = 8.00 Hz, 2H), 7.19 (d, *J* = 7.50 Hz, 1H), 7.11 (d, *J* = 7.38 Hz, 2H), 7.04 (t, *J* = 7.38 Hz, 2H), 6.98 (t, *J* = 6.50 Hz, 2H), 6.79 (d, *J* = 8.04 Hz, 1H), 6.61 (d, *J* = 7.64 Hz, 1H), 6.55 (t, *J* = 7.58 Hz, 1H), 6.00 (s, 1H), 5.12 (d, *J* = 7.62 Hz, 1H), 3.03 (d, *J* = 9.98 Hz, 1H), 2.72-2.57 (m, 2H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 194.9, 176.8, 152.4, 144.6, 138.8, 137.7, 135.7, 134.2, 133.7, 133.4, 129.9, 129.3, 128.6, 128.4, 128.2, 128.0, 127.8, 127.4, 127.0, 126.8, 126.5, 125.9, 125.5, 124.2, 123.7, 110.2, 68.3, 62.5, 39.1, 35.9, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), 1mL/min; minor enantiomer *t*_R = 36.49 min, major enantiomer *t*_R = 17.34 min. HRMS (ESI): [M+H]⁺ calcd for [C₃₇H₃₀NO₅S]:600.1839, found:600.1845.

(2'R,3R,4'R)-4'-(2-oxo-2-(*o*-tolyl)ethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ba).



White solid (120 mg, 98 %). PE/EA/DCM = 10/1/2, 200-202 °C. $[\alpha]_D^{24.7} = -45$ (c 1.0, CH₂Cl₂, 93 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.86 Hz, H), 7.59 (d, *J* = 7.86 Hz, 2H), 7.53 (t, *J* = 7.74 Hz, 1H), 7.37 (d, *J* = 7.86 Hz, 1H), 7.32 (d, *J* = 7.84 Hz, 3H), 7.23-7.20 (m, 2H), 7.18-7.15 (m, 1H), 7.11 (d, *J* = 7.62 Hz, 2H), 7.03 (t, *J* = 7.52 Hz, 2H), 6.95 (t, *J* = 8.18 Hz, 2H), 6.75 (d, *J* = 7.84 Hz, 1H), 6.60 (d, *J* = 7.64 Hz, 1H), 6.53 (t, *J* = 7.64 Hz, 1H), 6.00 (s, 1H), 5.11 (d, *J* = 7.64 Hz, 1H), 3.00 (d, *J* = 10.46 Hz, 1H), 2.64-2.48 (m, 2H), 2.42 (s, 3H), 2.36 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 198.0, 176.8, 152.4, 144.5, 138.8, 138.4, 137.8, 136.4, 134.1, 134.0, 132.1, 131.7, 130.0, 129.2, 128.4, 128.3, 128.1, 128.0, 127.3, 127.0, 126.8, 126.3, 125.9, 125.7, 125.4, 124.3, 123.6, 110.1, 68.3, 62.4, 39.5, 38.3, 21.6, 21.1. The enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 70:30), 1mL/min; minor enantiomer *t*_R = 10.39 min, major enantiomer *t*_R = 6.07 min. HRMS (ESI): [M+H]⁺ calcd for [C₃₈H₃₂NO₅S]:614.1996, found:614.2000.


(2'R,3R,4'R)-4'-(2-oxo-2-(*m*-tolyl)ethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ca).



White solid (120 mg, 98 %). PE/EA/DCM = 10/1/2, m. p.:186-190 °C. $[\alpha]_D^{25.3} = -27$ (c 1.0, CH₂Cl₂, 97 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.80 Hz, 1H), 7.60 (d, *J* = 7.78 Hz, 2H), 7.54 (s, 1H), 7.51 (t, *J* = 5.82 Hz, 2H), 7.35-7.27 (m, 4H), 7.19 (t, *J* = 7.34 Hz, 1H), 7.12 (d, *J* = 7.22 Hz, 2H), 7.04 (t, *J* = 7.26 Hz, 2H), 7.00-6.97 (m, 2H), 6.79 (d, *J* = 7.92 Hz, 1H), 6.62 (d, *J* = 7.44 Hz, 1H), 6.55 (t, *J* = 7.50 Hz, 1H), 5.99 (s, 1H), 5.12 (d, *J* = 7.44 Hz, 1H), 3.03 (d, *J* = 9.56 Hz, 1H), 2.70-2.57 (m, 2H), 2.40 (s, 3H), 2.36 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 195.1, 176.8, 152.3, 144.5, 138.7, 138.4, 137.6, 135.7, 134.2, 134.1, 133.7, 129.9, 129.3, 128.4, 128.4, 128.2, 128.1, 128.0, 127.3, 126.9, 126.8, 126.5, 125.8, 125.5, 125.0, 124.2, 123.7, 110.1, 68.3, 62.4, 39.0, 36.0, 21.6, 21.2. The enantiomeric excess was determined by HPLC with an IC


column. (*n*-hexane:*i*-PrOH = 75:25), mL/min; minor enantiomer t_R = 29.13 min, major enantiomer t_R = 14.53 min. HRMS (ESI): $[M+H]^+$ calcd for $[C_{38}H_{32}NO_5S]$:614.1996, found:614.1996.

(2'R,3R,4'R)-4'-(2-oxo-2-(*p*-tolyl)ethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3da).




White solid (121.6 mg, 99 %). PE/EA/DCM = 10/1/2, m. p.:220-226 °C. $[\alpha]_D^{24.6} = -18$ (*c* 1.0, CH_2Cl_2 , 94 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.11 (dd, J = 0.96 Hz, J = 7.98 Hz, 1H), 7.61 (t, J = 8.22 Hz, 4H), 7.51 (t, J = 7.50 Hz, 1H), 7.31 (t, J = 8.08 Hz, 2H), 7.19-7.16 (m, 3H), 7.11 (d, J = 7.40 Hz, 2H), 7.03 (t, J = 7.46 Hz, 2H), 7.00-6.95 (m, 2H), 6.78 (d, J = 7.76 Hz, 1H), 6.62 (d, J = 7.76 Hz, 1H), 6.55 (td, J = 7.68 Hz, J = 0.92 Hz, 1H), 5.99 (s, 1H), 5.12 (dd, J = 0.8 Hz, J = 7.68 Hz, 1H), 3.03 (d, J = 8.84 Hz, 1H), 2.69-2.53 (m, 2H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 194.5, 176.8, 152.4, 144.5, 144.2, 138.8, 137.7, 134.2, 133.9, 133.3, 129.9, 129.3, 129.2, 128.3, 128.2, 128.0, 127.9, 127.3, 127.0, 126.8, 126.6, 125.9, 125.5, 124.3, 123.7, 110.1, 68.3, 62.5, 39.1, 35.8, 21.5. The enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 90:10), mL/min; minor enantiomer t_R = 14.97 min, major enantiomer t_R = 18.13 min. HRMS (ESI): $[M+K]^+$ calcd for $[C_{38}H_{31}NO_5K]$:652.1555, found:652.1565.

(2'R,3R,4'R)-4'-(2-(2-methoxyphenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ea).



White solid (118 mg, 94 %). PE/EA/DCM = 10/1/2, m. p.:242-244 °C. $[\alpha]_D^{25.2} = -23$ (*c* 1.0, CH_2Cl_2 , 90 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.10 (d, J = 7.24 Hz, 1H), 7.63-7.59 (m, 3H), 7.51 (t, J = 7.66 Hz, 1H), 7.43-7.39 (m, 1H), 7.35 (d, J = 8.08 Hz, 2H), 7.20-7.17 (m, 1H), 7.12 (d, J = 7.40 Hz, 2H), 7.03 (t, J = 7.52 Hz, 2H), 6.95 (t, J = 7.44 Hz, 3H), 6.84 (d, J = 8.42 Hz, 1H), 6.67 (d, J = 8.00 Hz, 1H), 6.62 (d, J = 7.82 Hz, 1H), 6.54-6.50 (m, 1H), 6.00 (s, 1H), 5.11 (d, J = 7.06 Hz, 1H), 3.61 (s, 3H), 3.95 (t, J = 6.64 Hz, 1H), 2.67 (d, J = 6.64 Hz, 2H), 2.44 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 196.6, 176.9, 158.5, 152.5, 144.5, 139.1, 137.7, 134.3, 134.1, 133.9, 130.3, 130.0, 129.0, 128.2, 128.2, 128.1, 127.3, 127.1, 126.9, 126.7, 126.7, 125.9, 125.5, 124.7, 123.5, 120.7, 111.5, 109.7, 67.9, 62.6, 55.0, 41.5, 39.3, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer t_R = 50.89 min, major enantiomer t_R = 23.96 min. HRMS (ESI): $[M+H]^+$ calcd for $[C_{38}H_{32}NO_6S]$:630.1945, found:630.1960.


(2'R,3R,4'R)-4'-(2-(3-methoxyphenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3fa).



White solid (120 mg, 94 %). m. p.:106-110 °C. $[\alpha]_D^{25.3} = -30$ (*c* 1.0, CH_2Cl_2 , 99% ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.11 (d, J = 8.00 Hz, 1H), 7.59 (d, J = 8.12 Hz, 2H), 7.52 (t, J = 7.66 Hz, 1H), 7.29 (d, J = 8.72 Hz, 5H), 7.20 (t, J = 7.42 Hz, 1H), 7.12-7.06 (m, 3H), 7.13 (t, J = 7.50 Hz, 2H), 7.02 (t, J = 7.46 Hz, 1H), 6.99-6.95 (m, 2H), 6.78 (d, J = 8.00 Hz, 1H), 6.66 (d, J = 7.82 Hz, 1H), 6.55 (t, J = 7.66 Hz, 1H), 6.00 (s, 1H), 5.11 (d, J = 7.80 Hz, 1H), 3.81 (s, 3H), 3.05 (dd, J = 3.00 Hz, J = 9.64 Hz, 1H), 2.69-2.57 (m, 2H), 2.38 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 194.9, 176.9, 159.7, 152.4, 144.5, 138.8, 137.7, 137.1, 134.3, 133.7, 129.9, 129.6, 129.3, 128.4, 128.2, 128.0, 127.4, 127.0, 126.9, 126.6, 125.9, 125.5, 124.2, 123.7, 120.4, 119.6, 112.4, 110.2, 68.3, 62.6, 55.3, 39.2, 36.2, 21.5. The enantiomeric excess was determined by HPLC


with an IC column. (*n*-hexane:*i*-PrOH = 70:30), mL/min; major enantiomer t_R = 14.267 min, minor enantiomer t_R = 28.490 min, HRMS (ESI): $[M+H]^+$ calcd for $[C_{38}H_{32}NO_6S]$:630.1945, found:630.1945.

(2'R,3R,4'R)-4'-(2-(4-methoxyphenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ga).




White solid (125 mg, 99 %). PE/EA/DCM = 10/1/2, m. p.:200-203 °C. $[\alpha]_D^{25.2} = -20$ (*c* 1.0, CH_2Cl_2 , 93 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.10 (d, J = 8.04 Hz, 1H), 7.20 (d, J = 8.68 Hz, 2H), 7.59 (d, J = 8.18 Hz, 2H), 7.51 (t, J = 7.80 Hz, 2H), 7.29 (d, J = 8.18 Hz, 2H), 7.18 (t, J = 7.36 Hz, 1H), 7.11 (d, J = 7.48 Hz, 2H), 7.02 (t, J = 7.46 Hz, 1H), 6.98-6.93 (m, 2H), 6.85 (d, J = 8.82 Hz, 2H), 6.77 (d, J = 7.97 Hz, 1H), 6.67 (t, J = 7.76 Hz, 1H), 6.54 (t, J = 7.54 Hz, 1H), 6.00 (s, 1H), 5.13 (d, J = 7.61 Hz, 1H), 3.79 (s, 3H), 3.05 (d, J = 8.90 Hz, 1H), 2.66-2.52 (m, 2H), 2.38 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193.4, 176.8, 163.6, 152.4, 144.5, 138.8, 137.6, 134.2, 133.9, 130.1, 129.8, 129.2, 128.8, 128.3, 128.0, 128.0, 127.3, 126.9, 126.8, 126.6, 125.8, 125.4, 124.2, 123.6, 113.6, 110.1, 68.3, 62.5, 55.3, 39.2, 35.6, 21.5. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer t_R = 27.445 min, minor enantiomer t_R = 54.057 min. HRMS (ESI): $[M+H]^+$ calcd for $[C_{38}H_{32}NO_6S]$: 630.1945, found: 630.1948.

(2'R,3R,4'R)-4'-(2-(2-fluorophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ha).



White solid (120 mg, 97 %). PE/EA/DCM = 10/1/2, m. p.:166-168 °C. $[\alpha]_D^{24.9} = -25$ (*c* 1.0, CH_2Cl_2 , 90 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.90 Hz, 1H), 7.72 (t, J = 7.00 Hz, 1H), 7.63(d, J = 8.10 Hz, 2H), 7.53 (t, J = 7.58 Hz, 1H), 7.49-7.44 (m, 1H), 7.37 (d, J = 8.02 Hz, 2H), 7.22-7.16 (m, 2H), 7.11 (d, J = 7.48 Hz, 2H), 7.03 (t, J = 7.60 Hz, 3H), 7.95 (t, J = 7.90 Hz, 2H), 6.76 (d, J = 8.00 Hz, 1H), 6.55-6.50 (m, 2H), 5.99 (s, 1H), 5.10 (d, J = 7.56 Hz, 1H), 2.99 (d, J = 9.05 Hz, 1H), 2.72-2.58 (m, 2H), 2.45 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193. (J = 4.1 Hz), 176.8, 161.6 (J = 254.2 Hz), 152.4, 144.5, 138.8, 137.7, 135.0 (J = 9.44 Hz), 134.2, 133.7, 130.3, 130.0, 129.2, 128.3 (J = 5.24 Hz), 128.0, 127.3, 127.0, 126.8, 126.4, 125.8, 125.3, 124.4 (J = 3.4 Hz), 124.2, 123.6, 116.6 (J = 23.6 Hz), 110.1, 68.1, 62.3, 40.8 (J = 8.5 Hz), 38.9, 21.6. The enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 95:5), mL/min; minor enantiomer t_R = 19.93 min, major enantiomer t_R = 34.36 min. HRMS (ESI): $[M+H]^+$ calcd for $[C_{37}H_{29}FNO_5S]$:618.1745, found:618.1745.


(2'R,3R,4'R)-4'-(2-(3-fluorophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ia).



White solid (118 mg, 95 %). PE/EA/DCM = 9/1/2, m. p.:180-182 °C. $[\alpha]_D^{24.8} = -19$ (*c* 1.0, CH_2Cl_2 , 77 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.86 Hz, 1H), 7.59 (d, J = 8.20 Hz, 2H), 7.55-7.51 (m, 1H), 7.48 (d, J = 7.82 Hz, 2H), 7.42 (d, J = 8.82 Hz, 1H), 7.38-7.34 (m, 1H), 7.30 (d, J = 8.20 Hz, 1H), 7.22-7.17 (m, 2H), 7.11 (d, J = 7.32 Hz, 1H), 7.02 (t, J = 7.52 Hz, 2H), 6.99-6.93 (m, 2H), 6.77 (d, J = 8.02 Hz, 1H), 6.58 (d, J = 7.63 Hz, 1H), 6.54 (t, J = 7.82 Hz, 1H), 6.00 (s, 1H), 5.13 (d, J = 7.76 Hz, 1H), 3.03 (d, J = 9.68 Hz, 1H), 2.70-2.53 (m, 2H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193.7, 176.7, 163.8, 161.4, 152.3, 144.5, 138.7, 137.7, 137.7, 134.2, 133.5, 130.4, 130.3, 129.9, 129.4, 128.5, 128.2, 128.0, 127.3, 126.9, 126.8, 126.3, 125.8, 125.4, 124.0,


123.7, 123.6, 120.5, 120.3, 114.5, 114.3, 110.2, 68.3, 62.4, 39.0, 36.1, 21.5. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer t_R = 16.66 min, minor enantiomer t_R = 35.40 min. HRMS (ESI): $[M+H]^+$ calcd for $[C_{37}H_{29}FNO_5S]$:618.1745, found:618.1745.

(2'R,3R,4'R)-4'-(2-(4-fluorophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ja).




White solid (99 mg, 80 %). PE/EA/DCM = 10/1/2, m. p.:168-170 °C. $[\alpha]_D^{24.9} = -29$ (*c* 1.0, CH_2Cl_2 , 99 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.80 Hz, 1H), 7.77-7.74 (m, 2H), 7.59 (d, J = 8.10 Hz, 2H), 7.53 (t, J = 7.60 Hz, 1H), 7.31 (d, J = 7.92 Hz, 2H), 7.20 (t, J = 7.52 Hz, 1H), 7.12-6.97 (m, 8H), 6.79 (d, J = 7.94 Hz, 1H), 6.60 (d, J = 7.70 Hz, 1H), 6.56 (t, J = 7.64 Hz, 1H), 5.98 (s, 1H), 5.11 (d, J = 7.64 Hz, 1H), 3.01 (d, J = 9.98 Hz, 1H), 2.69-2.54 (m, 2H), 2.41 (s, 1H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193.4, 176.8, 167.0, 164.5, 152.3, 144.6, 138.7, 137.6, 134.1, 133.6, 132.1, 132.1, 130.6, 130.5, 129.9, 129.4, 128.5, 128.3, 128.1, 127.4, 127.0, 126.9, 126.4, 125.9, 125.5, 124.1, 123.7, 115.8, 115.6, 110.2, 68.3, 62.5, 39.0, 35.9, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer t_R = 13.70 min, minor enantiomer t_R = 29.58 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{28}FNO_5SNa]$:640.1564, found:640.1573.

(2'R,3R,4'R)-4'-(2-(2-chlorophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ka).



White solid (120 mg, 95 %), PE/EA/DCM = 10/1/2, m. p.:170-173 °C. $[\alpha]_D^{25} = -45$ (*c* 1.0, CH_2Cl_2 , 90 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.92 Hz, 1H), 7.61 (d, J = 8.18 Hz, 2H), 7.55 (t, J = 7.64 Hz, 1H), 7.37-7.32 (m, 5H), 7.28-7.22 (m, 2H), 7.10 (d, J = 7.44 Hz, 2H), 7.03 (t, J = 7.46 Hz, 2H), 6.98-6.92 (m, 2H), 6.73 (d, J = 8.02 Hz, 1H), 6.67 (d, J = 7.60 Hz, 1H), 6.51 (t, J = 7.58 Hz, 1H), 5.97 (s, 1H), 5.09 (d, J = 7.76 Hz, 1H), 2.95 (dd, J = 4.30 Hz, J = 8.30 Hz, 1H), 2.67-2.57 (m, 2H), 2.44 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 197.3, 176.7, 152.4, 144.6, 138.8, 137.9, 137.8, 134.2, 133.5, 132.1, 130.9, 130.7, 130.0, 129.3, 129.0, 128.5, 128.4, 128.1, 127.4, 127.0, 126.9, 126.8, 126.5, 125.9, 125.4, 124.1, 123.6, 110.1, 68.2, 62.4, 40.2, 39.4, 21.6. The enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 70:30), mL/min; minor enantiomer t_R = 15.58 min, major enantiomer t_R = 7.47 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{28}ClNO_5SNa]$:656.1269, found:656.1271.


(2'R,3R,4'R)-4'-(2-(3-chlorophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3la).



White solid (123 mg, 97 %), PE/EA/DCM = 10/1/2, m. p.:190-193 °C. $[\alpha]_D^{25.1} = -17$ (*c* 1.0, CH_2Cl_2 , 97 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.90 Hz, 1H), 7.70 (s, 1H), 7.59 (d, J = 8.24 Hz, 3H), 7.56-7.50 (m, 2H), 7.36-7.30 (m, 3H), 7.20 (t, J = 7.40 Hz, 1H), 7.11 (d, J = 7.36 Hz, 2H), 7.04 (t, J = 7.42 Hz, 2H), 7.01-6.95 (m, 2H), 6.79 (d, J = 8.02 Hz, 1H), 6.59-6.54 (m, 2H), 5.98 (s, 1H), 5.12 (d, J = 7.58 Hz, 1H), 3.02 (d, J = 8.84 Hz, 1H), 2.68-2.53 (m, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193.8, 176.8, 152.4, 144.6, 138.7, 137.7, 137.2, 135.0, 134.2, 133.5, 134.2, 133.5, 133.4, 130.0, 129.9, 129.4, 128.5, 128.3, 128.1, 127.9, 127.4, 127.0, 126.9, 126.4, 126.0, 125.9, 125.5, 124.1, 123.8, 110.3, 68.4, 62.5, 39.0, 36.1, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 75:25),


mL/min; major enantiomer t_R = 12.76 min, minor enantiomer t_R = 25.37 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{28}ClNO_5SNa]$:656.1269, found:656.1269.

(2'R,3R,4'R)-4'-(2-(4-chlorophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ma).




Light yellow solid (124 mg, 98%), PE/EA/DCM = 10/1/2, m. p.:186-190 °C. $[\alpha]_D^{25.1} = -5$ (c 1.0, CH_2Cl_2 , 99% ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.94 Hz, 1H), 7.66 (d, J = 8.42 Hz, 2H), 7.58 (d, J = 7.94 Hz, 2H), 7.53 (t, J = 7.60 Hz, 1H), 7.35 (d, J = 8.42 Hz, 2H), 7.29 (d, J = 8.04 Hz, 2H), 7.19 (t, J = 7.46 Hz, 1H), 7.11 (d, J = 7.36 Hz, 2H), 7.03 (t, J = 7.36 Hz, 2H), 6.99-6.95 (m, 2H), 6.77 (d, J = 8.04 Hz, 1H), 6.61 (d, J = 7.56 Hz, 1H), 6.55 (t, J = 7.66 Hz, 1H), 5.99 (s, 1H), 5.12 (d, J = 7.56 Hz, 1H), 3.02 (d, J = 9.48 Hz, 1H), 2.68-2.54 (m, 2H), 2.39 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193.8, 176.8, 152.4, 144.5, 139.8, 138.7, 137.7, 134.2, 134.0, 133.5, 129.9, 129.4, 129.2, 128.9, 128.5, 128.2, 128.0, 127.4, 127.0, 126.8, 126.4, 125.8, 125.5, 124.1, 123.7, 110.2, 68.3, 62.5, 39.1, 36.0, 21.5. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer t_R = 14.48 min, major enantiomer t_R = 18.03 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{28}ClNO_5SNa]$:656.1269, found:656.1273.

(2'R,3R,4'R)-4'-(2-(2-bromophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3na).



White solid (133 mg, 98%). PE/EA/DCM = 10/1/2, m. p.:206-209 °C. $[\alpha]_D^{24.9} = -62$ (c 1.0, CH_2Cl_2 , 90% ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.92 Hz, 1H), 7.61 (d, J = 8.12 Hz, 2H), 7.55 (t, J = 8.20 Hz, 2H), 7.36 (d, J = 7.92 Hz, 2H), 7.28-7.24 (m, 4H), 7.10 (d, J = 7.44 Hz, 2H), 7.03 (t, J = 7.40 Hz, 2H), 6.95 (dd, J = 7.30 Hz, 17.94 Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 6.51 (t, J = 7.60 Hz, 1H), 5.97 (s, 1H), 5.09 (d, J = 7.56 Hz, 1H), 2.91 (d, J = 9.72 Hz, 1H), 2.68-2.53 (m, 2H), 2.43 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 198.1, 176.7, 152.3, 144.6, 140.1, 138.7, 137.7, 134.1, 133.9, 133.5, 132.0, 132.0, 129.3, 128.5, 128.4, 128.1, 127.4, 127.4, 127.0, 126.8, 126.6, 125.8, 125.4, 124.1, 123.6, 118.7, 110.1, 68.1, 62.4, 39.7, 39.3, 21.7. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer t_R = 35.24 min, major enantiomer t_R = 16.42 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{28}BrNO_5SNa]$:700.0764, found:700.0766.


(2'R,3R,4'R)-4'-(2-(3-bromophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3oa).



White solid (132 mg, 97 %). PE/EA/DCM = 10/1/2, m. p.:180-185 °C. $[\alpha]_D^{25.1} = -16$ (c 1.0, CH_2Cl_2 , 99% ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.64 Hz, 1H), 7.86 (s, 1H), 7.67-7.62 (m, 2H), 7.58 (d, J = 8.04 Hz, 2H), 7.53 (t, J = 7.76 Hz, 1H), 7.31 (d, J = 8.30 Hz, 2H), 7.27-7.24 (m, 1H), 7.20 (t, J = 7.44 Hz, 1H), 7.11 (d, J = 7.44 Hz, 2H), 7.01-6.95 (m, 2H), 6.79 (t, J = 8.16 Hz, 1H), 6.57 (dd, J = 7.64 Hz, J = 14.00 Hz, 2H), 5.98 (s, 1H), 5.11 (d, J = 7.64 Hz, 1H), 3.02 (d, J = 8.98 Hz, 1H), 2.68-2.53 (m, 2H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193.7, 176.8, 152.4, 144.6, 138.6, 137.7, 137.4, 136.3, 134.2, 133.4, 130.8, 130.2, 129.9, 129.4, 128.5, 128.3, 128.1, 127.4, 127.0, 129.6, 126.4, 126.3, 125.9, 125.5, 124.0, 123.8, 123.0, 110.2, 68.4, 62.5, 39.0, 36.1, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 75:25), mL/min; minor enantiomer t_R = 30.91 min, major enantiomer t_R =


15.37 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{28}BrNO_5SNa]$:700.0764, found:700.0766.

(2'R,3R,4'R)-4'-(2-(4-bromophenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3pa).




White solid (134 mg, 99%). PE/EA/DCM = 11/1/2, m. p.:187-190 °C. $[\alpha]_D^{24.6} = 2$ (c 1.0, CH_2Cl_2 , 90% ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.84 Hz, 1H), 7.58 (d, J = 8.22 Hz, 4H), 7.52 (d, J = 8.34 Hz, 3H), 7.30 (d, J = 7.90 Hz, 2H), 7.19 (t, J = 7.44 Hz, 1H), 7.11 (d, J = 7.28 Hz, 2H), 7.03 (t, J = 7.34 Hz, 1H), 7.00-6.96 (m, 2H), 6.78 (d, J = 7.96 Hz, 1H), 6.59 (d, J = 7.72 Hz, 1H), 6.55 (t, J = 7.80 Hz, 1H), 5.98 (s, 1H), 5.11 (d, J = 7.58 Hz, 1H), 3.01 (d, J = 9.76 Hz, 1H), 2.67-2.53 (m, 2H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 194.0, 176.8, 152.3, 144.5, 138.6, 137.6, 134.3, 134.1, 133.5, 131.9, 129.9, 129.4, 129.3, 128.6, 128.5, 128.2, 128.0, 127.4, 126.9, 126.9, 126.3, 125.8, 125.4, 124.0, 123.7, 110.2, 68.3, 62.4, 39.0, 35.9, 21.6. The enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 90:10), mL/min; minor enantiomer t_R = 21.70 min, major enantiomer t_R = 17.59 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{28}BrNO_5SNa]$:700.0764, found:700.0764.

(2'R,3R,4'R)-4'-(2-(3,4-dimethoxyphenyl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3qa).



White solid (130 mg, 99%). PE/EA/DCM = 5/1/2, m. p.:180-186 °C. $[\alpha]_D^{23.2} = -10$ (c 1.0, CH_2Cl_2 , 99 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.11 (d, J = 7.92 Hz, 1H), 7.58 (d, J = 8.00 Hz, 2H), 7.53 (t, J = 7.58 Hz, 1H), 7.34 (s, 1H), 7.31 (d, J = 8.58 Hz, 1H), 7.26-7.25 (m, 2H), 7.21 (d, J = 7.62 Hz, 1H), 7.12 (d, J = 7.62 Hz, 2H), 7.04 (t, J = 7.62 Hz, 2H), 7.00-6.96 (m, 2H), 6.82-6.77 (m, 3H), 6.56 (d, J = 7.66 Hz, 1H), 6.00 (s, 1H), 5.12 (d, J = 7.80 Hz, 1H), 3.91 (s, 6H), 3.06 (d, J = 7.50 Hz, 1H), 2.66-2.55 (m, 2H), 2.34 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193.9, 176.9, 153.4, 152.4, 148.8, 144.4, 138.7, 137.6, 134.3, 133.7, 129.7, 129.3, 128.8, 128.4, 128.0, 127.3, 126.9, 126.9, 126.7, 125.8, 125.5, 124.1, 123.7, 122.6, 110.1, 109.9, 109.8, 68.3, 62.7, 55.9, 55.9, 39.5, 35.7, 21.4. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 70:30), mL/min; minor enantiomer t_R = 35.56 min, major enantiomer t_R = 72.25 min. HRMS (ESI): $[M+K]^+$ calcd for $[C_{39}H_{33}NO_7SK]$:682.1870, found:682.1870.


(2'R,3R,4'R)-4'-(2-(naphthalen-1-yl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ra).



White solid (117 mg, 90 %). PE/EA/DCM = 7/1/2, m. p.:210-212 °C. $[\alpha]_D^{26.8} = 36$ (c 1.0, CH_2Cl_2 , 99% ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.43 (d, J = 8.40 Hz, 1H), 8.14 (d, J = 7.96 Hz, 1H), 7.96 (d, J = 8.04 Hz, 1H), 7.85 (d, J = 7.84 Hz, 1H), 7.65-7.62 (m, 3H), 7.58-7.52 (m, 3H), 7.39 (t, J = 7.66 Hz, 1H), 7.34 (d, J = 8.06 Hz, 2H), 7.18 (t, J = 7.66 Hz, 1H), 7.13 (d, J = 7.46 Hz, 1H), 7.04 (t, J = 7.48 Hz, 2H), 6.99-6.94 (m, 2H), 6.77 (d, J = 8.04 Hz, 1H), 6.72 (d, J = 8.02 Hz, 1H), 6.53 (t, J = 7.60 Hz, 1H), 6.03 (s, 1H), 5.12 (d, J = 7.60 Hz, 1H), 3.15-3.11 (m, 1H), 2.79-2.70 (m, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 198.3, 176.9, 152.4, 144.6, 138.8, 137.9, 134.2, 134.0, 133.9, 133.3, 130.0, 129.3, 128.5, 128.4, 128.1, 127.6, 127.4, 127.1, 126.9, 126.5, 126.5, 125.9, 125.5, 125.4, 124.3, 124.1, 123.7, 110.2, 68.4, 62.5, 39.7, 38.7, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer t_R = 11.12 min, major enantiomer t_R = 17.69 min. HRMS (ESI):


[M+K]⁺ calcd for [C₄₁H₃₁NO₅SK]:688.1555, found:688.1554.

(2'R,3R,4'R)-4'-(2-(naphthalen-2-yl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3sa).




White solid (128 mg, 99 %). PE/EA/DCM = 10/1/2, m. p.: 206-210 °C. $[\alpha]_D^{26.9} = 30$ (c 1.0, CH₂Cl₂, 97 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.22 (s, 1H), 8.13 (d, *J* = 7.86 Hz, 1H), 7.92 (d, *J* = 7.98 Hz, 1H), 7.83 (d, *J* = 11.12 Hz, 3H), 7.60-7.51 (m, 5H), 7.20 (d, *J* = 7.66 Hz, 1H), 7.14 (t, *J* = 7.74 Hz, 4H), 7.05 (t, *J* = 7.70 Hz, 2H), 7.01-7.69 (m, 2H), 6.82 (t, *J* = 8.00 Hz, 2H), 6.57 (t, *J* = 7.82 Hz, 1H), 6.05 (s, 1H), 5.15 (d, *J* = 7.66 Hz, 1H), 3.14 (dd, *J* = 3.10 Hz, *J* = 9.54 Hz, 1H), 2.81-2.71 (m, 2H), 2.18 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 195.2, 177.0, 152.4, 144.4, 138.7, 137.6, 135.5, 134.2, 133.7, 132.8, 132.2, 129.8, 129.7, 129.5, 129.3, 128.7, 128.5, 128.4, 128.1, 128.0, 127.6, 127.4, 126.9, 126.8, 126.7, 125.9, 125.5, 124.1, 123.7, 123.4, 110.2, 68.4, 62.7, 39.5, 36.3, 21.3002E The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer *t_R* = 19.00 min, minor enantiomer *t_R* = 43.47 min. HRMS (ESI): [M+K]⁺ calcd for [C₄₁H₃₁NO₅SK]:688.1555, found:688.1555.

(2'R,3R,4'R)-4'-(2-(furan-2-yl)-2-oxoethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ta).



White solid (117 mg, 99 %). PE/EA/DCM = 7/1/2, m. p.: 150-154 °C. $[\alpha]_D^{26.4} = -24$ (c 1.0, CH₂Cl₂, 92 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.11 (d, *J* = 7.86 Hz, 1H), 7.58-7.48 (m, 4H), 7.30 (d, *J* = 8.04 Hz, 2H), 7.21 (t, *J* = 7.64 Hz, 1H), 7.11 (d, *J* = 7.42 Hz, 2H), 7.06-7.01 (m, 3H), 6.99-6.95 (m, 2H), 6.76 (d, *J* = 8.10 Hz, 1H), 6.73 (d, *J* = 7.76 Hz, 1H), 6.55 (t, *J* = 7.60 Hz, 1H), 6.47 (d, *J* = 1.86 Hz, 1H), 5.97 (s, 1H), 5.12 (d, *J* = 7.60 Hz, 1H), 2.97 (d, *J* = 9.96 Hz, 1H), 2.59-2.43 (m, 2H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 184.2, 176.7, 152.4, 151.5, 146.4, 144.5, 138.7, 137.6, 134.2, 133.5, 129.9, 129.3, 128.5, 128.2, 128.0, 127.3, 127.0, 126.9, 126.6, 125.9, 125.4, 124.1, 123.6, 117.2, 112.3, 110.1, 68.2, 62.5, 38.8, 35.9, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer *t_R* = 20.68 min, minor enantiomer *t_R* = 40.16 min. HRMS (ESI): [M+K]⁺ calcd for [C₃₅H₂₇NO₆SK]:628.1191, found:628.1190.


(2'R,3R,4'R)-4'-(2-oxo-2-(thiophen-2-yl)ethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ua).



White solid (119 mg, 99 %). PE/EA/DCM = 7/1/2, m. p.: 170-174 °C. $[\alpha]_D^{26.3} = -23$ (c 1.0, CH₂Cl₂, 96 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.11 (d, *J* = 7.90 Hz, 1H), 7.60 (d, *J* = 4.70 Hz, 1H), 7.57-7.52 (m, 3H), 7.47 (d, *J* = 3.30 Hz, 1H), 7.21-7.23 (m, 3H), 7.11 (d, *J* = 7.36 Hz, 2H), 7.07-7.02 (m, 3H), 6.97 (d, *J* = 7.16 Hz, 2H), 6.82 (d, *J* = 7.62 Hz, 1H), 6.77 (d, *J* = 8.00 Hz, 1H), 6.55 (t, *J* = 7.58 Hz, 1H), 5.99 (s, 1H), 5.12 (d, *J* = 7.60 Hz, 1H), 2.99 (dd, *J* = 4.80 Hz, *J* = 8.10 Hz, 1H), 2.61-2.52 (m, 2H), 2.37 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 188.1, 176.8, 152.4, 144.6, 142.9, 138.7, 137.6, 134.1, 134.1, 133.5, 132.0, 129.8, 129.4, 128.5, 128.2, 128.1, 128.1, 127.4, 127.0, 126.9, 126.6, 125.8, 125.5, 124.0, 123.7, 110.1, 68.3, 62.6, 39.3, 36.7, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer *t_R* = 18.50 min, minor enantiomer *t_R* = 40.47 min. HRMS (ESI): [M+K]⁺ calcd for [C₃₅H₂₇NO₅S₂K]:644.0962, found:644.0961.


(2'R,3R,4'R)-4'-(2-oxopropyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'

-quinolin]-2-one (3va).




White solid (64 mg, 60 %). PE/EA/DCM = 10/1/2, m. p.: 110-116 °C. $[\alpha]_D^{26.7} = -30$ (c 1.0, CH₂Cl₂, 82 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.11 (d, *J* = 7.92 Hz, 1H), 7.60-7.53 (m, 3H), 7.33 (d, *J* = 8.08 Hz, 2H), 7.25 (d, *J* = 14.92 Hz, 1H), 7.08 (d, *J* = 7.24 Hz, 2H), 7.03 (t, *J* = 7.46 Hz, 2H), 6.98-6.94 (m, 2H), 6.74 (d, *J* = 8.08 Hz, 1H), 6.53 (t, *J* = 7.56 Hz, 1H), 5.95 (s, 1H), 5.07 (d, *J* = 7.46 Hz, 1H), 2.77 (t, *J* = 6.84 Hz, 1H), 2.43 (s, 3H), 2.07 (t, *J* = 2.08 Hz, 1H), 2.05 (s, 1H), 1.89 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 203.8, 176.8, 152.4, 144.5, 138.7, 137.7, 134.4, 133.5, 129.9, 129.3, 128.6, 128.4, 128.1, 127.4, 127.1, 127.0, 126.2, 125.8, 125.4, 124.0, 123.7, 68.2, 62.4, 41.3, 39.0, 29.1, 21.5. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer *t*_R = 19.80 min, minor enantiomer *t*_R = 31.25 min. HRMS (ESI): $[M+K]^+$ calcd for [C₃₂H₂₇NO₅SK]:576.1242, found:576.1241.

(2'R,3R,4'R)-6'-chloro-4'-(2-oxo-2-phenylethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3wa).




White solid (123 mg, 97 %). PE/EA/DCM = 10/1/2, m. p.:190-192 °C. $[\alpha]_D^{25.3} = 39$ (c 1.0, CH₂Cl₂, 95 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.07 (d, *J* = 8.46 Hz, 1H), 7.71 (d, *J* = 7.66 Hz, 2H), 7.63 (d, *J* = 8.06 Hz, 2H), 7.56-7.50 (m, 2H), 7.42-7.35 (m, 4H), 7.09-6.96 (m, 6H), 6.81 (d, *J* = 8.22 Hz, 1H), 6.62 (t, *J* = 7.64 Hz, 1H), 6.58 (s, 1H), 5.96 (s, 1H), 5.27 (d, *J* = 7.68 Hz, 1H), 2.96 (t, *J* = 6.28 Hz, 1H), 2.63 (d, *J* = 6.24 Hz, 2H), 2.42 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 194.5, 176.6, 152.3, 144.9, 138.3, 136.3, 135.7, 135.5, 133.8, 133.5, 132.6, 130.1, 129.5, 129.3, 128.6, 128.6, 128.1, 127.8, 127.5, 127.0, 126.7, 125.8, 125.2, 123.9, 123.8, 110.4, 68.2, 62.2, 38.9, 35.8, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 90:10), mL/min; minor enantiomer *t*_R = 14.40 min, major enantiomer *t*_R = 10.43 min. HRMS (ESI): $[M+Na]^+$ calcd for [C₃₇H₂₈ClNO₅SNa]:656.1269, found:656.1269.

(2'R,3R,4'R)-2'-(2-methoxyphenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ab).



White solid (114 mg, 90 %). PE/EA/DCM = 10/1/2, m. p.:206-214 °C. $[\alpha]_D^{23.5} = -24$ (c 1.0, CH₂Cl₂, 99 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.19 (d, *J* = 7.92 Hz, 1H), 7.74 (d, *J* = 8.12 Hz, 2H), 7.68 (d, *J* = 7.56 Hz, 2H), 7.57 (d, *J* = 7.54 Hz, 1H), 7.53-7.47 (m, 2H), 7.37 (t, *J* = 7.70 Hz, 2H), 7.29 (d, *J* = 8.12 Hz, 2H), 7.15 (t, *J* = 7.56 Hz, 2H), 6.99-6.92 (m, 3H), 6.78 (d, *J* = 7.54 Hz, 1H), 6.56 (d, *J* = 7.74 Hz, 1H), 6.37-6.33 (m, 3H), 5.02 (d, *J* = 7.56 Hz, 1H), 3.51 (s, 3H), 3.06 (dd, *J* = 9.74 Hz, *J* = 3.00 Hz, 1H), 2.67-2.55 (m, 2H), 2.36 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 195.0, 177.2, 154.7, 152.7, 144.1, 137.4, 135.9, 135.7, 134.0, 133.2, 129.9, 128.8, 128.6, 128.5, 128.4, 128.2, 128.1, 127.7, 127.1, 126.9, 126.7, 126.1, 125.3, 125.2, 122.9, 120.2, 109.4, 108.6, 62.8, 60.8, 53.5, 39.6, 35.1, 21.5. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer *t*_R = 23.50 min, major enantiomer *t*_R = 26.08 min. HRMS (ESI): $[M+Na]^+$ calcd for [C₃₈H₃₁NO₆SNa]:652.1764, found:652.1770.


(2'R,3R,4'R)-2'-(3-methoxyphenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ac).



White solid (116 mg, 92 %). PE/EA/DCM = 10/1/2, m. p.:98-106 °C. $[\alpha]_D^{23.4} = -23$ (c 1.0, CH₂Cl₂, 91 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.11 (d, *J* = 7.56


Hz, 1H), 7.71 (d, $J = 7.34$ Hz, 2H), 7.60 (d, $J = 8.26$ Hz, 2H), 7.54-7.49 (m, 2H), 7.38 (t, $J = 7.72$ Hz, 2H), 7.31 (d, $J = 8.08$ Hz, 2H), 7.18 (t, $J = 7.46$ Hz, 1H), 7.01-6.93 (m, 2H), 6.81 (d, $J = 8.08$ Hz, 1H), 6.61 (d, $J = 7.72$ Hz, 1H), 6.66 (s, 1H), 6.60 (d, $J = 7.72$ Hz, 1H), 6.55 (d, $J = 7.60$ Hz, 1H), 6.50 (dd, $J = 2.04$ Hz, $J = 8.06$ Hz, 1H), 5.98 (s, 3H), 5.12 (d, $J = 7.36$ Hz, 1H), 3.61 (s, 3H), 3.02 (d, $J = 9.02$ Hz, 1H), 2.71-2.56 (m, 2H), 2.40 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 194.9, 175.9, 152.8, 144.5, 139.1, 137.8, 135.5, 134.7, 133.5, 133.4, 132.5, 130.5, 130.0, 129.4, 128.8, 128.6, 128.5, 128.4, 127.8, 127.2, 127.0, 126.6, 126.4, 125.8, 124.2, 123.4, 121.1, 110.5, 68.1, 62.4, 54.9, 39.1, 35.9, 21.6$. The enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 90:10), mL/min; minor enantiomer $t_R = 16.81$ min, major enantiomer $t_R = 18.44$ min. $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{38}\text{H}_{31}\text{NO}_6\text{SNa}]$:652.1764, found:652.1764.

(2'R,3R,4'R)-2'-(4-methoxyphenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ad).




White solid (121 mg, 97 %). PE/EA/DCM = 7/1/2, m. p.:210-212 °C. $[\alpha]_D^{23.1} = -36$ (c 1.0, CH_2Cl_2 , 99 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.08$ (d, $J = 7.88$ Hz, 1H), 7.71 (d, $J = 7.52$ Hz, 2H), 7.58 (d, $J = 8.32$ Hz, 2H), 7.54-7.49 (m, 2H), 7.38 (t, $J = 7.78$ Hz, 2H), 7.30 (d, $J = 8.04$ Hz, 2H), 7.18 (t, $J = 7.60$ Hz, 1H), 7.04-6.97 (m, 3H), 6.79 (d, $J = 8.04$ Hz, 1H), 6.61 (d, $J = 7.68$ Hz, 1H), 6.59-6.55 (m, 3H), 5.93 (s, 1H), 5.14 (d, $J = 7.60$ Hz, 1H), 3.60 (s, 3H), 3.03 (d, $J = 9.64$ Hz, 1H), 2.71-2.55 (m, 2H), 2.39 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 194.9, 176.8, 158.5, 152.4, 144.5, 137.7, 135.7, 134.1, 133.8, 133.3, 130.9, 129.9, 129.3, 128.5, 128.3, 128.1, 127.7, 127.2, 127.0, 126.8, 126.5, 125.4, 124.3, 123.7, 113.4, 110.2, 68.7, 62.6, 54.9, 39.0, 36.0, 21.5$. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 75:25), mL/min; minor enantiomer $t_R = 47.23$ min, major enantiomer $t_R = 16.45$ min. $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{38}\text{H}_{31}\text{NO}_6\text{SNa}]$:652.1764, found:652.1767.

(2'S,3R,4'R)-2'-(2-fluorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ae).



White solid (114 mg, 92 %), PE/EA/DCM = 10/1/2, m. p.:230-236 °C. $[\alpha]_D^{24.5} = 27$ (c 1.0, CH_2Cl_2 , >99 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.12$ (d, $J = 7.26$ Hz, 1H), 7.70 (d, $J = 7.40$ Hz, 4H), 7.53 (t, $J = 6.80$ Hz, 2H), 7.39 (t, $J = 7.78$ Hz, 3H), 7.32 (d, $J = 8.16$ Hz, 2H), 7.19 (t, $J = 7.56$ Hz, 1H), 7.04-6.91 (m, 4H), 6.68 (t, $J = 9.10$ Hz, 1H), 6.61 (d, $J = 7.68$ Hz, 1H), 6.48 (s, 1H), 6.39 (s, 1H), 5.08 (d, $J = 6.50$ Hz, 1H), 3.04 (t, $J = 6.20$ Hz, 1H), 2.69-2.59 (m, 2H), 2.39 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 194.8, 176.5, 152.9, 144.6, 137.3, 135.8, 134.8, 133.9, 133.4, 130.0, 129.3, 129.1, 128.6, 128.4, 128.3, 128.1, 127.8, 127.1, 126.4, 125.4, 124.3, 123.9$ ($J = 2.8$ Hz), 123.5, 114.6 ($J = 24.6$ Hz), 110.3, 61.6 ($J = 60.6$ Hz), 39.4, 35.5, 29.6, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer $t_R = 23.32$ min, major enantiomer $t_R = 19.27$ min. HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{37}\text{H}_{29}\text{FNO}_5\text{S}]$:618.1745, found:618.1748.


(2'R,3R,4'R)-2'-(3-fluorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3af).



White solid (112 mg, 90 %), PE/EA/DCM = 10/1/2, m. p.:228-232 °C. $[\alpha]_D^{24.8} = -30$ (c 1.0, CH_2Cl_2 , 99 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.11$ (d, $J = 7.84$ Hz, 1H), 7.71 (d, $J = 7.66$ Hz, 2H), 7.59 (d, $J = 8.28$ Hz, 2H), 7.53 (t, $J = 7.50$ Hz, 2H), 7.39 (t, $J = 7.66$ Hz, 2H), 7.31 (t, $J = 7.98$ Hz, 2H), 7.19 (t, $J = 7.80$ Hz,


1H), 7.04-6.99 (m, 2H), 6.90-6.81 (m, 3H), 6.66 (td, $J = 8.24$ Hz, $J = 1.60$ Hz, 1H), 6.62-6.56 (m, 2H), 5.98 (s, 1H), 5.12 (d, $J = 7.62$ Hz, 1H), 3.02 (d, $J = 10.06$ Hz, 1H), 2.72-2.55 (m, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 194.8, 176.7, 162.3$ ($J = 247.0$ Hz), 152.4, 144.8, 141.5 ($J = 6.9$ Hz), 137.4, 135.7, 134.0, 133.6, 133.4, 130.0, 129.7 ($J = 8.3$ Hz), 129.5, 128.6, 128.5, 128.2, 127.8, 127.0, 126.6, 125.4, 123.9, 121.5 ($J = 2.6$ Hz), 114.5 ($J = 21.6$ Hz), 113.3 ($J = 22.8$ Hz), 110.3, 67.7, 62.3, 39.1, 35.8, 29.5, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer $t_R = 6.66$ min, minor enantiomer $t_R = 11.93$ min. HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{37}\text{H}_{29}\text{FNO}_5\text{S}]$:618.1745, found:618.1750.

(2'R,3R,4'R)-2'-(4-fluorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ag).




White solid (118 mg, 95 %), PE/EA/DCM = 10/1/2, m. p.:190-192 °C. $[\alpha]_D^{24.1} = -60$ (c 1.0, CH_2Cl_2 , 93 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.09$ (d, $J = 7.92$ Hz, 1H), 7.72 (d, $J = 7.60$ Hz, 2H), 7.58 (d, $J = 8.10$ Hz, 2H), 7.52 (t, $J = 6.70$ Hz, 2H), 7.38 (t, $J = 7.60$ Hz, 2H), 7.32 (d, $J = 7.90$ Hz, 2H), 7.19 (t, $J = 7.32$ Hz, 1H), 7.11-7.08 (m, 2H), 7.01 (t, $J = 7.68$ Hz, 1H), 6.81 (d, $J = 8.04$ Hz, 1H), 6.73 (t, $J = 8.52$ Hz, 2H), 6.63-6.56 (m, 2H), 5.95 (s, 1H), 5.13 (d, $J = 7.74$ Hz, 1H), 3.02 (d, $J = 10.28$ Hz, 1H), 2.73-2.56 (m, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 194.8, 176.7, 161.6$ ($J = 248.3$ Hz), 152.4, 144.7, 139.4, 137.5, 135.7, 134.7 ($J = 3.2$ Hz), 133.9, 133.6, 133.4, 129.9, 129.5, 128.5 ($J = 12.5$ Hz), 128.1, 127.7 ($J = 6.0$ Hz), 126.9 ($J = 4.26$ Hz), 126.6, 125.3, 123.9 ($J = 15.4$ Hz), 122.4, 116.0 ($J = 22.0$ Hz), 115.0 ($J = 21.6$ Hz), 110.7 ($J = 85.5$ Hz), 67.8, 62.4, 39.0, 35.9, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 70:30), mL/min; minor enantiomer $t_R = 12.72$ min, major enantiomer $t_R = 10.82$ min. HRMS (ESI): $[\text{M}+\text{K}]^+$ calcd for $[\text{C}_{37}\text{H}_{28}\text{FNO}_5\text{SK}]$:656.1304, found:656.1309.

(2'S,3R,4'R)-2'-(2-chlorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ah).



White solid (124 mg, 98 %). PE/EA/DCM = 7/1/2, m. p.:238-242 °C. $[\alpha]_D^{23.0} = -31$ (c 1.0, CH_2Cl_2 , 99 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.09$ (d, $J = 7.88$ Hz, 1H), 7.71 (dd, $J = 5.52$ Hz, $J = 7.46$ Hz, 4H), 7.54 (t, $J = 7.82$ Hz, 2H), 7.39 (t, $J = 7.76$ Hz, 2H), 7.34 (d, $J = 8.30$ Hz, 2H), 7.26-7.20 (m, 2H), 7.09-7.01 (m, 2H), 6.95-9.68 (m, 3H), 6.67 (d, $J = 7.68$ Hz, 1H), 6.57 (t, $J = 7.60$ Hz, 1H), 6.52 (s, 1H), 5.30 (d, $J = 7.56$ Hz, 1H), 3.10 (d, $J = 6.62$ Hz, 1H), 2.69-2.54 (m, 2H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 195.0, 176.3, 152.9, 144.6, 137.9, 137.7, 135.9, 134.9, 133.6, 133.4, 131.2, 130.1, 129.9, 129.4, 129.1, 128.6, 128.6, 128.5, 127.9, 127.2, 127.0, 126.5, 126.2, 125.8, 124.3, 123.4, 110.5, 63.6, 61.1, 39.4, 35.8, 21.7$. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 70:30), mL/min; minor enantiomer $t_R = 10.31$ min, major enantiomer $t_R = 14.11$ min. HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{37}\text{H}_{29}\text{ClNO}_5\text{S}]$:634.1449, found:634.1453.


(2'R,3R,4'R)-2'-(3-chlorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ai).



White solid (124 mg, 99 %), PE/EA/DCM = 7/1/2, m. p.:97-100 °C. $[\alpha]_D^{23.7} = -14$ (c 1.0, CH_2Cl_2 , 99 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.01$ (d, $J = 7.80$ Hz, 1H), 7.72 (d, $J = 7.46$ Hz, 2H), 7.58 (d, $J = 8.22$ Hz, 2H), 7.55-7.51 (m, 2H),


7.38 (t, $J = 7.72$ Hz, 2H), 7.32 (d, $J = 8.14$ Hz, 2H), 7.20 (t, $J = 7.46$ Hz, 1H), 7.10 (s, 1H), 7.04-7.93 (m, 4H), 6.83 (d, $J = 8.06$ Hz, 1H), 6.60 (d, $J = 7.34$ Hz, 2H), 5.94 (s, 1H), 5.13 (d, $J = 7.55$ Hz, 1H), 3.00 (d, $J = 10.10$ Hz, 1H), 2.73-2.55 (m, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 194.7, 176.6, 152.4, 144.8, 140.9, 137.4, 135.7, 134.0, 133.6, 133.4, 130.0, 129.6, 129.4, 128.6, 128.5, 128.2, 127.7, 127.6, 127.0, 127.0, 126.6, 126.3, 125.3, 124.1, 123.9, 123.8, 110.4, 67.7, 62.3, 39.0, 35.9, 21.6$. The enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 90:10), mL/min; minor enantiomer $t_R = 12.72$ min, major enantiomer $t_R = 10.82$ min. HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{37}\text{H}_{29}\text{ClNO}_5\text{S}]$:634.1449, found:634.1449.

(2'R,3R,4'R)-2'-(4-chlorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3aj).




White solid (118 mg, 93 %). PE/EA/DCM = 9/1/2, m. p.:200-202 °C. $[\alpha]_D^{23.8} = -29$ (c 1.0, CH_2Cl_2 , 99 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.09$ (d, $J = 7.82$ Hz, 1H), 7.72 (d, $J = 7.58$ Hz, 2H), 7.58 (d, $J = 8.12$ Hz, 2H), 7.53-7.50 (m, 2H), 7.39 (t, $J = 7.58$ Hz, 2H), 7.32 (d, $J = 7.94$ Hz, 2H), 7.19 (t, $J = 7.58$ Hz, 1H), 7.07-7.01 (m, 5H), 6.83 (d, $J = 8.02$ Hz, 1H), 6.61-6.57 (m, 2H), 5.93 (s, 1H), 5.12 (d, $J = 7.74$ Hz, 1H), 3.01 (d, $J = 10.34$ Hz, 1H), 2.72-2.56 (m, 2H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 194.8, 176.6, 152.4, 144.8, 137.4, 135.7, 133.8, 133.6, 133.4, 133.1, 130.0, 129.6, 128.6, 128.5, 128.3, 128.1, 127.8, 127.4, 127.0, 126.6, 125.3, 123.9, 123.9, 110.4, 67.8, 62.2, 39.0, 35.9, 21.6$. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer $t_R = 13.84$ min, minor enantiomer $t_R = 22.38$ min. HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{37}\text{H}_{29}\text{ClNO}_5\text{S}]$:634.1449, found:634.1454.

(2'S,3R,4'R)-2'-(2-bromophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ak).



White solid (126 mg, 93 %). PE/EA/DCM = 10/1/2, m. p.:198-200 °C. $[\alpha]_D^{23.9} = -75$ (c 1.0, CH_2Cl_2 , 99 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.06$ (d, $J = 7.84$ Hz, 1H), 7.72 (t, $J = 8.44$ Hz, 4H), 7.55-7.51 (m, 2H), 7.40-7.34 (m, 4H), 7.27 (d, $J = 7.90$ Hz, 1H), 7.22 (d, $J = 7.62$ Hz, 1H), 7.16 (d, $J = 7.40$ Hz, 1H), 7.03 (t, $J = 7.74$ Hz, 1H), 6.94 (t, $J = 7.50$ Hz, 1H), 6.88 (d, $J = 8.00$ Hz, 1H), 6.82 (t, $J = 7.16$ Hz, 1H), 6.69 (d, $J = 7.74$ Hz, 1H), 6.60 (t, $J = 7.62$ Hz, 1H), 6.50 (s, 1H), 5.36 (d, $J = 7.56$ Hz, 1H), 3.10 (d, $J = 10.40$ Hz, 1H), 2.71-2.64 (m, 1H), 2.55 (dd, $J = 1.54$ Hz, $J = 17.40$ Hz, 1H), 2.40 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 194.9, 175.9, 152.8, 144.5, 139.1, 137.8, 135.8, 134.7, 133.5, 133.4, 132.5, 130.5, 130.0, 129.4, 128.8, 128.6, 128.5, 128.4, 127.8, 127.2, 127.0, 126.6, 126.4, 125.8, 124.2, 123.4, 121.1, 110.5, 65.4, 61.1, 39.2, 35.8, 21.6$. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer $t_R = 10.15$ min, major enantiomer $t_R = 18.33$ min. HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{37}\text{H}_{29}\text{BrNO}_5\text{S}]$:678.0944, found:678.0949.


(2'R,3R,4'R)-2'-(3-bromophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3al).



White solid (134 mg, 99 %), PE/EA/DCM = 7/1/2, m. p.:110-112 °C. $[\alpha]_D^{23.8} = -18$ (c 1.0, CH_2Cl_2 , 94 % ee); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.10$ (d, $J = 7.90$ Hz, 1H), 7.72 (d, $J = 7.58$ Hz, 2H), 7.58 (d, $J = 8.10$ Hz, 2H), 7.53 (d, $J = 7.00$ Hz, 2H), 7.39 (t, $J = 7.58$ Hz, 2H), 7.33 (d, $J = 7.90$ Hz, 2H), 7.24 (s, 1H), 7.20 (t, $J = 7.58$ Hz, 1H), 7.10 (d, $J = 8.00$ Hz, 1H), 7.06-7.00 (m, 2H), 6.91 (t, $J =$


7.90 Hz, 1H), 6.83 (d, J = 8.00 Hz, 1H), 6.61 (t, J = 6.98 Hz, 2H), 5.92 (s, 1H), 5.13 (d, J = 7.58 Hz, 1H), 3.00 (d, J = 10.42 Hz, 1H), 2.74-2.66 (m, 1H), 2.57 (d, J = 16.74 Hz, 1H), 2.42 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ = 194.7, 176.6, 152.4, 144.8, 141.0, 137.3, 135.7, 133.8, 133.5, 133.4, 130.5, 130.0, 129.6, 129.2, 128.6, 128.2, 127.7, 127.0, 127.0, 126.6, 125.3, 124.6, 123.9, 123.8, 122.2, 110.4, 67.6, 62.3, 38.9, 35.9, 21.6. The enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 90:10), mL/min; minor enantiomer t_R = 11.54 min, major enantiomer t_R = 12.91 min. HRMS (ESI): $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{37}\text{H}_{29}\text{BrNO}_5\text{S}]$:678.0944, found:678.0944.

(2'R,3R,4'R)-2'-(4-bromophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3am).




White solid (134 mg, 99 %), PE/EA/DCM = 7/1/2, m. p.:201-203 °C. $[\alpha]_D^{25.0}$ = - 43 (*c* 1.0, CH_2Cl_2 , >99 % ee); ^1H NMR (400 MHz, CDCl_3): δ = 8.12 (d, J = 7.92 Hz, 1H), 7.58 (d, J = 8.20 Hz, 4H), 7.52 (d, J = 8.30 Hz, 3H), 7.30 (d, J = 7.80 Hz, 2H), 7.19 (t, J = 7.42 Hz, 1H), 7.11 (d, J = 7.30 Hz, 2H), 7.03 (t, J = 7.36 Hz, 2H), 6.97 (d, J = 6.42 Hz, 2H), 6.78 (d, J = 7.92 Hz, 1H), 6.59 (d, J = 7.80 Hz, 1H), 6.55 (t, J = 7.78 Hz, 1H), 5.98 (s, 1H), 5.11 (d, J = 7.56 Hz, 1H), 3.01 (d, J = 9.82 Hz, 1H), 2.67-2.53 (m, 2H), 2.48 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ = 194.0, 176.8, 152.3, 144.5, 138.6, 137.6, 134.3, 134.1, 133.5, 131.9, 129.9, 129.3, 128.6, 128.5, 128.2, 128.0, 127.4, 126.9, 126.3, 125.8, 125.4, 124.0, 123.7, 110.2, 68.3, 62.4, 39.0, 35.9, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; major enantiomer t_R = 14.71 min, minor enantiomer t_R = 28.57 min. $[\text{M}+\text{H}]^+$ calcd for $[\text{C}_{37}\text{H}_{29}\text{BrNO}_5\text{S}]$:678.0944, found:678.0947.

(2'S,3R,4'R)-2'-(2,3-dichlorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3an).



White solid (124 mg, 93 %). PE/EA/DCM = 10/1/2, m. p.:182-186 °C. $[\alpha]_D^{24.3}$ = - 109 (*c* 1.0, CH_2Cl_2 , 96 % ee); ^1H NMR (400 MHz, CDCl_3): δ = 8.08 (dd, J = 0.70 Hz, J = 7.94 Hz, 1H), 7.72-7.68 (m, 4H), 7.56-7.51 (m, 2H), 7.40-7.34 (m, 4H), 7.23-7.19 (m, 2H), 7.10-7.03 (m, 2H), 6.39-6.87 (m, 2H), 6.67 (d, J = 7.86 Hz, 1H), 6.58 (td, J = 7.62 Hz, J = 0.80 Hz, 1H), 6.55 (s, 1H), 5.30 (dd, J = 7.66 Hz, J = 0.66 Hz, 1H), 3.10 (d, J = 9.80 Hz, 1H), 2.70-2.53 (m, 2H), 2.40 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ = 194.8, 176.1, 152.8, 144.7, 140.1, 137.5, 135.7, 134.6, 133.4, 133.4, 132.6, 130.1, 129.6, 129.5, 129.3, 128.6, 128.5, 128.3, 128.1, 127.7, 127.1, 126.5, 126.4, 125.5, 123.9, 123.5, 110.7, 64.0, 60.8, 39.4, 35.5, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer t_R = 19.24 min, major enantiomer t_R = 22.50 min. HRMS (ESI): $[\text{M}+\text{Na}]^+$ calcd for $[\text{C}_{37}\text{H}_{27}\text{Cl}_2\text{NO}_5\text{SNa}]$:690.0879, found:690.0880.


(2'S,3R,4'R)-2'-(2,3-dichlorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ao).



Light yellow solid (118 mg, 90 %). PE/EA/DCM = 10/1/2, m. p.:188-192 °C. $[\alpha]_D^{24.4}$ = 46 (*c* 1.0, CH_2Cl_2 , 99 % ee); ^1H NMR (400 MHz, CDCl_3): δ = 8.09 (d, J = 8.08 Hz, 1H), 7.70 (d, J = 6.70 Hz, 4H), 7.58-7.51 (m, 2H), 7.38 (dd, J = 7.62, J = 17.82 Hz, 4H), 7.24 (d, J = 14.94 Hz, 1H), 7.18 (d, J = 2.10 Hz, 1H), 7.07 (t, J = 7.68 Hz, 1H), 7.01 (d, J = 8.64 Hz, 1H), 6.92-6.87 (m, 2H), 6.66 (t, J = 7.78 Hz, 2H), 6.45 (s, 1H), 5.31 (d, J = 7.60 Hz, 1H), 3.07 (d, J = 10.32 Hz,


1H), 2.72-2.52 (m, 2H), 2.41 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 194.7, 175.9, 152.8, 144.8, 139.2, 137.4, 135.8, 134.5, 132.1, 130.2, 130.1, 129.7, 129.3, 128.7, 128.6, 128.4, 127.8, 127.2, 127.1, 126.5, 125.6, 123.9, 123.6, 110.7, 63.3, 60.9, 39.2, 35.7, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer *t_R* = 7.03 min, major enantiomer *t_R* = 13.98 min. HRMS (ESI): [M+Na]⁺ calcd for [C₃₇H₂₇Cl₂NO₅SNa]:690.0879, found:690.0885.

(2'R,3R,4'R)-2'-(3,4-dichlorophenyl)-4'-(2-oxo-2-phenylethyl)-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ap).




White solid (126 mg, 95 %). PE/EA/DCM = 10/1/2, m. p.:200-206 °C. [α]_D^{23.2} = - 21 (*c* 1.0, CH₂Cl₂, 97 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.09 (d, *J* = 7.96 Hz, 1H), 7.71 (d, *J* = 7.60 Hz, 2H), 7.58-7.52 (m, 4H), 7.39 (t, *J* = 7.70 Hz, 2H), 7.33 (d, *J* = 8.20 Hz, 2H), 7.22-7.18 (m, 2H), 7.12 (d, *J* = 8.32 Hz, 1H), 7.06 (t, *J* = 7.72 Hz, 1H), 6.96 (dd, *J* = 1.84 Hz, *J* = 8.32 Hz, 1H), 6.86 (d, *J* = 8.10 Hz, 1H), 6.65-6.59 (m, 2H), 5.88 (s, 1H), 5.13 (d, *J* = 7.66 Hz, 1H), 2.98(d, *J* = 10.12 Hz, 1H), 2.73-2.54 (m, 2H), 2.42 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 194.7, 176.4, 152.4, 145.0, 139.2, 137.2, 135.7, 133.6, 133.5, 133.4, 132.3, 131.5, 130.1, 130.1, 129.9, 128.6, 128.3, 128.1, 127.8, 127.1, 127.0, 126.6, 125.5, 125.2, 124.1, 123.6, 110.6, 67.3, 62.1, 39.0, 35.9, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer *t_R* = 18.29 min, major enantiomer *t_R* = 11.26 min. HRMS (ESI): [M+Na]⁺ calcd for [C₃₇H₂₇Cl₂NO₅SNa]:690.0879, found:690.0879.

(2'R,3R,4'R)-5-methyl-4'-(2-oxo-2-phenylethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3aq).



White solid (120 mg, 98 %). PE/EA/DCM = 10/1/2, m. p.:198-202 °C. [α]_D^{26.6} = - 30 (*c* 1.0, CH₂Cl₂, 96 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.86 Hz, 1H), 7.73 (d, *J* = 7.48 Hz, 2H), 7.60 (d, *J* = 8.20 Hz, 2H), 7.53 (t, *J* = 7.48 Hz, 2H), 7.39 (t, *J* = 7.60 Hz, 2H), 7.31 (d, *J* = 8.06 Hz, 2H), 7.19 (t, *J* = 7.48 Hz, 2H), 7.11 (d, *J* = 7.42 Hz, 1H), 7.05 (t, *J* = 7.48 Hz, 2H), 6.98 (d, *J* = 7.14 Hz, 1H), 6.77 (d, *J* = 8.06 Hz, 1H), 6.66 (d, *J* = 8.20 Hz, 1H), 6.61 (d, *J* = 7.80 Hz, 1H), 5.98 (s, 1H), 4.83 (s, 1H), 3.00 (d, *J* = 9.36 Hz, 1H), 2.72-2.57 (m, 2H), 2.40 (m, 3H), 1.86 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 195.1, 177.2, 150.5, 144.6, 138.9, 137.9, 135.9, 134.3, 134.0, 133.4, 133.2, 130.0, 129.7, 128.6, 128.4, 128.1, 127.9, 127.4, 127.1, 126.8, 126.7, 126.1, 126.0, 124.1, 109.7, 68.4, 62.7, 39.2, 36.1, 21.7, 20.9. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 75:25), mL/min; major enantiomer *t_R* = 12.67 min, minor enantiomer *t_R* = 22.28 min. HRMS (ESI): [M+Na]⁺ calcd for [C₃₈H₃₁NO₅SNa]: 636.1815, found: 636.1814.

(2'R,3R,4'R)-5-chloro-4'-(2-oxo-2-phenylethyl)-2'-phenyl-1'-tosyl-2',4'-dihydro-1'H,2H-spiro[benzofuran-3,3'-quinolin]-2-one (3ar).




White solid (126 mg, 99 %). PE/EA/DCM = 10/1/2, m. p.:160-164 °C. [α]_D^{26.8} = - 13 (*c* 1.0, CH₂Cl₂, 87 % ee); ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.86 Hz, 1H), 7.73 (d, *J* = 7.40 Hz, 2H), 7.61-7.52 (m, 4H), 7.40 (t, *J* = 7.40 Hz, 2H), 7.32 (d, *J* = 7.76 Hz, 2H), 7.21 (d, *J* = 7.60 Hz, 1H), 7.10-7.06 (m, 4H), 7.01 (d, *J* = 4.98 Hz, 1H), 6.95 (d, *J* = 8.14 Hz, 1H), 6.72 (d, *J* = 8.60 Hz, 1H), 6.62 (d, *J* = 7.50 Hz, 1H), 5.98 (s, 1H), 4.99 (s, 1H), 3.05 (d, *J* = 10.50 Hz, 1H), 2.75-2.55 (m, 2H), 2.41 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 194.6, 176.1, 150.8, 144.7, 138.4, 137.5, 135.7, 134.1,

133.5, 133.3, 130.0, 129.4, 129.0, 128.7, 128.6, 128.4, 128.3, 127.8, 127.6, 127.0, 126.5, 126.1, 125.8, 125.7, 111.3, 68.2, 62.9, 39.0, 35.8, 21.6. The enantiomeric excess was determined by HPLC with an IC column. (*n*-hexane:*i*-PrOH = 75:25), mL/min; major enantiomer t_R = 10.39 min, minor enantiomer t_R = 15.47 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{28}ClNO_5SNa]$: 656.1269, found: 656.1268.

2.5 Analytical data of compounds of 4.

(3-chlorophenyl)-2-((2'*R*,3*R*,4'*R*)-2-oxo-2'-phenyl-1'-tosyl-2',4'-dihydro-1'*H*,2*H*-spiro[benzofuran-3,3'-quinolin]-4'-yl)acetate (4la).




White solid (124 mg, 95 %). PE/EA/DCM = 10/1/2, m. p.: 182-186 °C. $[\alpha]_D^{24.3}$ = -50 (*c* 1.0, CH_2Cl_2 , 95 % ee); 1H NMR (400 MHz, $CDCl_3$): δ = 8.12 (d, J = 7.98 Hz, 1H), 7.70 (s, 1H), 7.58 (d, J = 8.06 Hz, 3H), 7.55-7.49 (m, 2H), 7.35-7.29 (m, 3H), 7.20 (t, J = 7.52 Hz, 1H), 7.11 (d, J = 7.34 Hz, 2H), 7.03 (t, J = 7.42 Hz, 1H), 7.00-6.95 (m, 2H), 3.03 (d, J = 9.62 Hz, 1H), 2.68-2.53 (m, 2H), 2.40 (m, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ = 193.7, 176.8, 152.4, 144.6, 138.7, 137.7, 137.2, 134.9, 134.2, 133.5, 133.3, 130.0, 129.9, 129.4, 128.5, 128.3, 128.1, 127.8, 127.4, 127.0, 126.9, 126.3, 125.9, 125.9, 125.5, 124.1, 123.8, 110.2, 68.4, 62.5, 39.0, 36.1, 21.6. enantiomeric excess was determined by HPLC with an IA column. (*n*-hexane:*i*-PrOH = 80:20), mL/min; minor enantiomer t_R = 9.25 min, major enantiomer t_R = 17.73 min. HRMS (ESI): $[M+Na]^+$ calcd for $[C_{37}H_{27}Cl_2NO_5SNa]$: 672.1224, found: 672.1230.

3. General Procedure to Synthesize the Spiro-Tetrahydroquinoline

Derivatives 3.


3.1. General procedure to construct spiro-tetrahydroquinoline derivatives.



To a vessel were successively added **1** (0.3 mmol), **2** (0.2 mmol), **cat. VIII** (0.04 mmol) in 4 mL 1,2-dichloroethane (DCE), The reaction was stirred at rt. for quantitative time. After the reactions were completed, the solvents were evaporated, and the residue was purified by flash silica gel chromatography (PE/EA/DCM = 10/1/2) to afford the desired product. The HPLC (racemate of **3ca**, **3da**, **3ea**, **3ga**, **3ia**, **3la**, **3ab**, **3ac**, **3ad**, **3ae**, **3al**, **3am**, **3ao**, **3ap**) were mixed through the equal quality catalyzed by **III** and **VIII** and the racemate of **3qa**, **3ra**, **3sa**, **3ta**, **3ua**, **3va**, **3aq**, **3ar** were catalyzed by 20 mol% TBD as the base under standard conditions, the others


racemates of **3** were catalyzed by DABCO (50 mol%). Furthermore, chiral **3aq** was synthesized by adjusting the ration of substrates: **1a** (0.2 mmol), **2q** (0.4 mmol), **cat.** (20 mol%) in 4 mL DCE at rt. for 36h due to the pure compound of **2q** could not be successfully obtained.

3.2. A gram-scale synthesis of **3la**.



To a round-bottomed flask were successively added **1la** (6.165g, 15 mmol), **2a** (2.22g, 10 mmol), **cat. VIII** (2 mmol, 20 mol%) in 1,2-dichloroethane (0.05M). The reaction was stirred at rt. for 50 h. After the reactions were completed, the solvents were evaporated, and the residue was purified by flash silica gel chromatography (PE/EA/DCM = 10/1/2) to afford the desired product as a white solid (95% yield, >20:1 dr, 97% ee.)

3.3. General procedure to synthesis **4la**.




To a vessel were successively added **3la** (0.2 mmol), *m*-CPBA (0.5 mmol), K_2HPO_4 (0.5 mmol) in 6 mL DCM. The reaction was stirred at rt. for 12 h, after the reactions were completed, the solvents were evaporated, and the residue was purified by flash silica gel chromatography (PE/EA/DCM = 10/1/2) to afford the desired product as a white solid.


4. Copy of NMR Spectrogram.

4.1 Copy of NMR Spectrogram of **2**.


1H NMR of **2a** (400M, $CDCl_3$)




¹³C NMR of 2a (100M, CDCl₃)




¹H NMR of 2b (400M, CDCl₃)




¹³CNMR of **2b** (100M, CDCl₃)




¹HNMR of **2c** (400M, CDCl₃)




¹³CNMR of **2c** (100M, CDCl₃)




¹HNMR of **2d** (400M, CDCl₃)






¹³CNMR of **2d** (100M, CDCl₃)



¹³CNMR of **2e** (400M, CDCl₃)




Chemical structure of **2e** (2-(2-fluorophenyl)-2-oxo-1,3-benzodioxole) is shown above the spectrum.


¹³C NMR spectrum (CDCl₃) peaks (ppm):

Peak (ppm)
168.22
165.78
159.22
154.54
132.92
132.88
132.49
132.49
132.49
131.24
129.88
129.88
124.19
124.15
123.72
122.99
122.99
122.15
122.01
122.01
116.33
116.16
111.14
77.32
77.00
76.68



27




¹³CNMR of 2g (100M, CDCl₃)




¹HNMR of 2h (400M, CDCl₃)


 ^{13}C NMR of **2h** (100M, CDCl_3)¹H NMR of **2i** (400M, CDCl₃)




¹³CNMR of **2i** (100M, CDCl₃)




¹HNMR of **2j** (400M, CDCl₃)




¹³CNMR of 2j (100M, CDCl₃)




¹HNMR of 2k (400M, CDCl₃)




¹³CNMR of **2k** (100M, CDCl₃)




¹HNMR of **2l** (400M, CDCl₃)




¹³CNMR of **21** (100M, CDCl₃)




¹H NMR of **2m** (400M, CDCl₃)




¹³C NMR of 2m (100M, CDCl₃)




¹H NMR of 2n (400M, CDCl₃)




¹³CNMR of **2n** (100M, CDCl₃)




¹HNMR of **2o** (400M, CDCl₃)




¹³CNMR of **2o** (100M, CDCl₃)




¹HNMR of **2p** (400M, CDCl₃)




¹³CNMR of **2p** (100M, CDCl₃)



¹HNMR of **2q** (400M, CDCl₃)




¹³CNMR of 2q (100M, CDCl₃)





4.2Copy of NMR Spectrogram of 3

¹HNMR of 3aa (400M, CDCl₃)




¹³CNMR of **3aa** (100M, CDCl₃)







¹³CNMR of 3ca (100M, CDCl₃)




¹HNMR of 3da (400M, CDCl₃)




¹³CNMR of **3ea** (100M, CDCl₃)




¹HNMR of **3fa** (400M, CDCl₃)




¹³CNMR of 3fa (100M, CDCl₃)




¹HNMR of 3ga (400M, CDCl₃)




¹³CNMR of **3ga** (100M, CDCl₃)




¹HNMR of **3ha** (400M, CDCl₃)




¹³CNMR of **3ha** (100M, CDCl₃)




¹HNMR of **3ia** (400M, CDCl₃)




¹³CNMR of 3ia (100M, CDCl₃)





¹HNMR of 3ja (400M, CDCl₃)




¹³CNMR of **3ja** (400M, CDCl₃)




¹HNMR of **3ka** (400M, CDCl₃)


 ^{13}C NMR of **3ka** (100M, CDCl_3)¹HNMR of **3la** (400M, CDCl₃)




¹³C NMR of 3la (100M, CDCl₃)




¹H NMR of 3ma (400M, CDCl₃)




¹³C NMR of 3ma (100M, CDCl₃)




¹H NMR of 3na (400M, CDCl₃)




¹³C NMR of 3na (100M, CDCl₃)




¹H NMR of 30a (400M, CDCl₃)




¹³CNMR of **30a** (100M, CDCl₃)




¹HNMR of **3pa** (400M, CDCl₃)




¹³CNMR of **3qa** (400M, CDCl₃)




¹HNMR of **3ra** (400M, CDCl₃)




¹³C NMR of 3sa (400M, CDCl₃)




¹H NMR of 3ta (400M, CDCl₃)




¹³CNMR of **3ta** (400M, CDCl₃)




¹HNMR of **3ua** (400M, CDCl₃)




¹³CNMR of **3ua** (400M, CDCl₃)




¹HNMR of **3va** (400M, CDCl₃)




¹³CNMR of 3va (400M, CDCl₃)




¹HNMR of 3wa (400M, CDCl₃)




¹³CNMR of **3wa** (400M, CDCl₃)




¹HNMR of **3ab** (400M, CDCl₃)




¹³CNMR of **3ac (100M, CDCl₃)**




¹³CNMR of **3ad (400M, CDCl₃)**




¹³CNMR of 3ad (100M, CDCl₃)





¹HNMR of 3ae (400M, CDCl₃)




¹³CNMR of 3af (100M, CDCl₃)




¹HNMR of 3ag (400M, CDCl₃)


 ^{13}C NMR of **3ah** (100M, CDCl_3)¹HNMR of **3ai** (400M, CDCl₃)




¹³CNMR of 3ai (100M, CDCl₃)




¹HNMR of 3aj (400M, CDCl₃)



¹³C NMR of 3aj (100M, CDCl₃)



¹H NMR of 3ak (400M, CDCl₃)




Chemical structure of 3ak: O=C1[C@H](c2ccccc2)C(=O)[C@@H](c3ccccc3)N1Cc4ccccc4Br


¹³C NMR spectrum (CDCl₃) data:

Chemical Shift (ppm)
194.94
175.99
152.85
144.57
139.84
138.81
135.81
134.73
133.73
133.41
132.54
130.72
130.06
128.45
128.83
128.63
128.48
128.50
127.21
127.21
127.03
126.61
126.44
125.89
125.42
125.42
121.18
110.57
77.31
77.00
76.68
65.45
61.13
39.23
35.81
21.66
21.18


3ak




¹³C NMR of 3al (400M, CDCl₃)





¹H NMR of 3am (400M, CDCl₃)




¹³CNMR of 3am (100M, CDCl₃)




¹HNMR of 3an (400M, CDCl₃)

 ^{13}C NMR of **3aq** (100M, CDCl_3)¹HNMR of **3ar** (400M, CDCl₃)




¹³CNMR of 3ar (100M, CDCl₃)




4.3 Copy of NMR Spectrogram of 4.

HNMR of 4a (400M, CDCl₃)




¹³CNMR of 4la (100M, CDCl₃)




5. HPLC spectrogram.

5.1. HPLC spectrogram of compound 3.

3aa




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	17.358	1.15828e4	208.11932	50.0524
2	DAD 250, 4 nm	36.371	1.15585e4	107.63284	49.9476




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	17.342	2.09784e4	435.78836	98.7841
2	DAD 250, 4 nm	36.493	258.21228	4.60982	1.2159

3ba




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	6.053	3865.71533	198.93677	51.8624
2	DAD 250, 4 nm	10.354	3588.08325	90.45081	48.1376




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	6.070	7052.77979	393.94077	96.2791
2	DAD 250, 4 nm	10.393	272.56815	9.98524	3.7209

3ca




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	14.580	1.81340e4	440.57251	54.0773
2	DAD 250, 4 nm	29.002	1.53995e4	188.53185	45.9227




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	14.539	4.31380e4	1054.91199	98.6308
2	DAD 250, 4 nm	29.133	598.83057	12.12469	1.3692

3da




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	14.784	4928.29980	89.58771	48.5955
2	DAD 250, 4 nm	17.917	5213.17871	89.28972	51.4045




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	14.979	607.71344	8.56677	2.9163
2	DAD 250, 4 nm	18.133	2.02311e4	239.45514	97.0837

3ea




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	23.011	6872.66602	94.28802	48.0131
2	DAD 250, 4 nm	49.726	7441.47363	50.36050	51.9869




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	23.966	3.83354e4	422.24863	95.1559
2	DAD 250, 4 nm	50.898	1951.53491	18.06255	4.8441

3fa




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	14.391	2.00347e4	436.27164	50.9378
2	DAD 250, 4 nm	28.524	1.92970e4	215.42924	49.0622




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	14.267	7.52313e4	1455.31104	99.9904
2	DAD 250, 4 nm	28.490	7.23830	1.00678	9.620e-3

3ga




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	27.412	1.68873e4	194.29408	33.9812
2	DAD 250, 4 nm	53.456	3.28087e4	196.25618	66.0188




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	27.445	3.45381e4	415.24982	96.5282
2	DAD 250, 4 nm	54.057	1242.23608	9.90807	3.4718

3ha




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	20.403	0.9934	7052.55811	49.7776
2	DAD 250, 4 nm	34.589	1.4431	7115.57910	50.2224




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	21.359	675.55219	11.30569	4.2601
2	DAD 250, 4 nm	39.195	1.51822e4	115.96967	95.7399

3ia




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	16.672	4.32177e4	742.42120	46.3847
2	DAD 250, 4 nm	35.258	4.99547e4	487.96448	53.6153




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	16.661	5.64118e4	1071.86475	88.3547
2	DAD 250, 4 nm	35.403	7435.19482	73.77364	11.6453

3ja




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	13.356	4.95393e4	1042.54248	50.8347
2	DAD 250, 4 nm	29.836	4.79125e4	486.72095	49.1653




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	13.709	6.26077e4	1217.32373	99.7231
2	DAD 250, 4 nm	29.518	173.85800	10.48030	0.2769

3ka




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 260, 4 nm	7.245	2741.87256	103.82861	49.7848
2	DAD 260, 4 nm	14.661	2765.57788	38.62230	50.2152




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 260, 4 nm	7.478	9449.63965	483.37592	95.1811
2	DAD 260, 4 nm	15.580	478.41986	13.06848	4.8189

3la




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 260, 4 nm	12.824	4.35237e4	956.93011	53.8628
2	DAD 260, 4 nm	25.413	3.72811e4	472.90057	46.1372




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 260, 4 nm	12.765	8.45612e4	1766.95386	98.6523
2	DAD 260, 4 nm	25.370	1155.19116	16.69323	1.3477

3ma




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	18.337	1.64716e4	294.52563	49.9713
2	DAD 250, 4 nm	40.714	1.64905e4	134.07349	50.0287




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	18.035	8.09576e4	1586.20813	99.8441
2	DAD 250, 4 nm	40.487	126.42647	3.55792	0.1559

3na




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	16.392	1.35207e4	261.14063	50.8641
2	DAD 250, 4 nm	35.091	1.30613e4	127.60278	49.1359




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	16.429	1.01928e4	206.11870	95.2244
2	DAD 250, 4 nm	35.247	511.18179	7.13670	4.7756

30a




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	15.187	1.39068e4	231.35269	50.0133
2	DAD 250, 4 nm	30.992	1.38994e4	145.49487	49.9867




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	15.379	1.79240e4	408.03281	99.9246
2	DAD 250, 4 nm	30.913	13.53295	1.11918	0.0754

3pa




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	17.091	7096.58691	143.76282	50.8430
2	DAD 250, 4 nm	20.643	6861.26123	98.40793	49.1570




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	17.591	4.35885e4	918.84094	95.6189
2	DAD 250, 4 nm	21.703	1997.17004	40.02856	4.3811

3qa




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	35.668	1.47099e4	98.03483	50.0432
2	DAD 250, 4 nm	72.143	1.46845e4	56.24397	49.9568




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	35.566	2.40554e4	178.58833	99.4946
2	DAD 250, 4 nm	72.253	122.19086	1.26997	0.5054

3ra




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	11.191	1.09992e4	415.67139	57.0671
2	DAD 250, 4 nm	17.519	8274.91797	111.07327	42.9329




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	11.126	6.78193	6.34107e-1	0.0500
2	DAD 250, 4 nm	17.696	1.35674e4	201.95763	99.9500

3sa




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 254, 4 nm	20.029	3.85763e4	503.32178	49.9278
2	DAD 254, 4 nm	43.472	3.86879e4	278.80356	50.0722




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 254, 4 nm	19.903	4.19067e4	637.88403	98.7082
2	DAD 254, 4 nm	43.499	548.43799	6.67292	1.2918

3ta




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 260, 4 nm	21.193	1.97732e4	1.97732e4	50.6467
2	DAD 260, 4 nm	40.866	1.92683e4	40.866	49.3533




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 260, 4 nm	20.683	5.90141e4	886.04303	96.0114
2	DAD 260, 4 nm	40.160	2451.61963	25.28139	3.9886

3ua




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 260, 4 nm	18.593	1.45535e4	238.09624	50.8614
2	DAD 260, 4 nm	40.616	1.40605e4	112.84756	49.1386




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 260, 4 nm	18.502	2.99928e4	484.77710	97.7303
2	DAD 260, 4 nm	40.470	696.55865	8.34602	2.2697

3va




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	19.799	19.799	152.89020	50.3917
2	DAD 260, 4 nm	30.867	30.867	111.04134	49.6083




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	19.860	2.18952e4	318.32214	91.2515
2	DAD 260, 4 nm	31.253	2099.13135	27.13150	8.7485

3qa




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	10.442	1.91928e4	659.83301	49.8602
2	DAD 250, 4 nm	14.389	1.93004e4	475.76855	50.1398




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	10.433	3.98394e4	1364.19592	97.5292
2	DAD 250, 4 nm	14.402	1009.30377	37.05903	2.4708

3ab




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	23.369	2.68786e4	367.89960	42.5137
2	DAD 250, 4 nm	26.120	3.63448e4	384.00610	57.4863




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	23.507	95.86879	2.58806	0.3067
2	DAD 250, 4 nm	26.085	3.11628e4	367.96957	99.6933

3ac




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	16.515	1.75938e4	354.12482	48.0240
2	DAD 250, 4 nm	18.210	1.90416e4	366.19574	51.9760




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	16.813	1381.38684	28.19214	4.5646
2	DAD 250, 4 nm	18.448	2.88817e4	525.61682	95.4354

3ad




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	16.447	4.83617e4	799.42596	64.9939
2	DAD 250, 4 nm	47.158	2.60479e4	175.96487	35.0061




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	16.453	5.75612e4	984.93774	99.9357
2	DAD 250, 4 nm	47.233	37.03231	0.00000	0.0643

3ae




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	19.241	2.96940e4	445.60284	44.6913
2	DAD 250, 4 nm	23.402	3.67485e4	492.79968	55.3087




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	19.278	4.12637e4	592.18701	99.8402
2	DAD 250, 4 nm	23.321	66.06526	4.45768	0.1598

3af




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	6.640	7814.92432	251.60643	50.4184
2	DAD 250, 4 nm	11.889	7685.23096	242.18611	49.5816




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	6.661	1.52919e4	462.95895	99.6399
2	DAD 250, 4 nm	11.935	55.25913	2.31000	0.3601

3ag




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	9.341	1.32303e4	495.82074	50.4281
2	DAD 250, 4 nm	14.270	1.30057e4	320.36255	49.5719




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	9.228	2.93502e4	1044.79028	96.5880
2	DAD 250, 4 nm	14.118	1036.80127	33.91952	3.4120

3ah




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	10.484	1.96023e4	452.89539	48.7679
2	DAD 250, 4 nm	14.206	2.05927e4	453.75775	51.2321




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	10.319	23.95238	3.35219	0.1074
2	DAD 250, 4 nm	14.117	2.22708e4	515.45367	99.8926

3ai




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	10.900	764.31610	26.76929	48.5199
2	DAD 250, 4 nm	12.640	810.94806	25.74880	51.4801




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	10.820	15.81770	2.15516	0.0904
2	DAD 250, 4 nm	12.726	1.74757e4	537.43689	99.9096

3aj




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	13.843	3.07664e4	625.15350	50.2371
2	DAD 250, 4 nm	22.392	3.04759e4	418.99353	49.7629




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	13.834	4.33991e4	1052.61572	99.9541
2	DAD 250, 4 nm	22.387	19.93125	1.98463	0.0459

3ak




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 230, 4 nm	10.335	1.28606e5	1637.72766	50.6019
2	DAD 230, 4 nm	18.412	1.25547e5	1697.66309	49.3981




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 230, 4 nm	10.159	46.23292	2.99066	0.0369
2	DAD 230, 4 nm	18.339	1.25382e5	1694.70581	99.9631

3al




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	11.586	9400.35449	241.84549	48.5417
2	DAD 250, 4 nm	13.014	9965.16211	245.89076	51.4583




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	11.540	869.25537	35.04445	2.9761
2	DAD 250, 4 nm	12.914	2.83385e4	825.12305	97.0239

3am




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	14.671	2.53226e4	510.63858	58.5561
2	DAD 250, 4 nm	28.296	1.79224e4	207.93053	41.4439




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	14.717	6.41367e4	1247.26099	99.7153
2	DAD 250, 4 nm	28.579	183.14842	6.85141	0.2847

3an




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 230, 4 nm	19.135	3.47173e4	548.51764	50.6430
2	DAD 230, 4 nm	22.152	3.38357e4	478.56949	49.3570




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 230, 4 nm	19.241	6.25079e4	1074.43774	98.1425
2	DAD 230, 4 nm	22.508	1183.06824	16.35461	1.8575

3ao




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	6.995	1.95291e4	432.42938	54.8084
2	DAD 250, 4 nm	14.077	1.61025e4	368.16867	45.1916




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	7.039	27.73716	2.77762	0.0924
2	DAD 250, 4 nm	13.984	2.99782e4	664.67035	99.9076

3ap




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	11.289	3.86402e4	802.77997	53.0966
2	DAD 250, 4 nm	18.251	3.41331e4	605.27765	46.9034




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	11.263	2.33624e4	565.45300	98.6482
2	DAD 250, 4 nm	18.298	320.13449	8.81148	1.3518

3aq




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	12.718	1.15386e4	278.02759	50.1328
2	DAD 250, 4 nm	22.289	1.15386e4	165.82906	49.8672




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	12.670	2.06397e4	479.73453	98.0569
2	DAD 250, 4 nm	22.287	409.00366	8.85773	1.9431

3ar




Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 254, 4 nm	10.387	1.31374e4	303.20697	49.2778
2	DAD 254, 4 nm	15.411	1.35225e4	254.07007	50.7222



Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 254, 4 nm	10.394	4.45007e4	1285.87891	93.7543
2	DAD 254, 4 nm	15.470	2964.55493	75.30211	6.2457


5.2. HPLC spectrogram of compound 4.

4la



Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	8.914	4.45007e4	1285.87891	93.7543
2	DAD 250, 4 nm	17.564	2964.55493	75.30211	6.2457

1	DAD 250, 4 nm	8.914	5.67747e4	1034.38721	48.2484
2	DAD 250, 4 nm	17.564	6.08971e4	1095.79749	51.7516



Peak	Processed Channel	Retention Time (min)	Peak Area (mAU*s)	Peak Height (mAU)	Peak Area (%)
1	DAD 250, 4 nm	9.255	1615.00354	46.72694	2.3261
2	DAD 250, 4 nm	17.730	6.78142e4	1218.31885	97.6739

6. X-ray crystallographic data


6. 1. Preparation of the crystal.

The pure compound (123 mg) of **3la** was dissolved in CDCl_3 and removed in NMR tube. After the NMR experiments were finished, the tube was placed in the lab for about one week, during which the crystal was formed. The X-ray was detected after the crystal was formed. The X-ray data was detected by Smart APEX II which was purchased from Bruker.



Name	X-Ray crystal diffractometer	Model	Smart APEX II
Serial number	010301990904001	Manufacturer	Bruker
Main Specifications	X-ray generating power: 3.0 kw, 4k 62mm CCD Overall light transmittance: 70% Light source yield: >170 e/Mo Photon Temperature range: 100 K- 298K		
Main accessories		Mo	

6. 2. X-ray Crystallographic Data of Compound 3la.



AbsCorr = MULTI-SCAN	
Data completeness = 1.71/0.91	Theta(max) = 76.023
R(reflections) = 0.0391(6395)	wR2(reflections)= 0.1057(6907)
S = 1.061	Npar = 453
Displacement ellipsoids are drawn at 50% probability level	

7. References.

- 1: a) Zhu, Y.-Y.; Li, B.-Y.; Wang, C.; Dong, Z.-H.; Zhong, X.-L.; Wang, K.-R.; Yan, W.-J.; Wang, R. *Org. Biomol. Chem.*, **2017**, *15*, 4544. b) Yang, W.; He, H.-X.; Gao, Y.; Du, D.-M. *Adv. Synth. Catal.* **2013**, *355*, 3670-3678.
- 2: a) Huang, Z.-S.; Yang, X.-Q.; Yang, F.-L.; Lu, T.; Zhou, Q.-F. *Org. Lett.* **2017**, *19*, 3524-3527. b) Chen, H.-G.; He, Y.-W.; Zhou, L. *Org. Chem. Front.*, **2018**, *5*, 3240-3244.